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Combining DNA demethylating agents (DNMTis) with histone deacetylase inhibitors 
(HDACis) holds promise for enhancing cancer immune therapy. Herein, pharmacologic 
and isoform specificity of HDACi’s are investigated to guide their addition to a DNMTi, 
thus devising a new, low-dose, sequential regimen which imparts a robust anti-tumor 
efect for non-smal cel lung cancer (NSCLC). Using in vitro treated NSCLC cel lines, 
we elucidate an Interferon-αβ based transcriptional program with accompanying 
upregulation of antigen presentation machinery mediated in part through dsRNA 
induction. This is accompanied by suppression of MYC signaling and an increase in the 
T cel chemoatractant, CCL5. Use of this combination treatment schema in mouse 
models of NSCLC reverses tumor immune evasion and modulates T-cel exhaustion 
state towards memory and efector T-cel phenotypes. Key correlative science metrics 
emerge for an upcoming clinical trial, testing enhancement of immune checkpoint 
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1. Disease specific background: Lung cancer 
 
The work presented herein focuses on therapeutic intervention for the leading cause of 
cancer deaths in the world, lung cancer. This disease is classified into 2 broad 
categories based on histological classification: smal cel and non-smal cel lung 
cancers. Approximately 85% of al lung cancers present as non-smal lung cancer 
(NSCLC) and this wil be the focus of the presented work. NSCLC is comprised of 3 
major subtypes: adenocarcinoma, squamous cel carcinoma, and large cel carcinomas 
(Herbst et al., 2008). The most prevalent type of NSCLC is adenocarcinoma which 
presents most commonly with either TP53 and Kras mutations, but rarely with both 
(Cancer Genome Atlas Research Network. 2014). Squamous cel carcinomas, the other 
dominant subtype have a high frequency of TP53 mutations (Cancer Genome Atlas 
Research Network., 2012). Deriving therapeutic eficacy in this solid malignancy has 
been problematic. While immune therapy has been a breakthrough for the management 
of this disease, only a minority of patients respond durably. A major chalenge for the 
field is increasing the proportion of patients who respond durably through derivations of 
both rational combination therapies and identification of biomarkers predictive of 
response beyond PD-L1 positivity alone. 
 







2.1 DNA Methylation 
DNA methylation is a stable modification with diferential functionality depending on the 
region of the genome incorporated. Promoter DNA methylation acts as a transcriptionaly 
repressive modification which recruits nuclear repressor complexes, thus instiling a 
repressive chromatin state which is negatively correlated with transcription factor binding 
(Jones, Baylin, 2007). Gene body methylation is associated with transcriptionaly active 
genes, although the causation of this modification in facilitating gene transcription is 
largely unknown and therefore may be merely corelated with the act of active 
transcription (Duymich et al., 2016). Enhancer methylation is even more elusive, while 
there is evidence that methylation of enhancers is anti-correlated with transcription factor 
binding and thus gene expression (Chartlet et al., 2016), other data suggests the 
necessity of DNA methylation and associated methyltransferases to maintain enhancer 
integrity and functionality (Rinaldi et al., 2016). DNA methylation is known to be 
dysregulated in malignancies with associated genome wide hypo and promoter 
associated hyper methylation, this coupled with the reversibility of this mark, makes the 
alteration of DNA methylation an atractive approach for the treatment of human cancer 
(Baylin, Jones, 2016). 
 
2.2 DNA Methyltransferases (DNMTs) 
DNA methyltransferases are comprised of 4 major isoforms: DNMT1, DNM3a, DNMT3b, 
DNMT3L. The maintenance methyltransferase DNMT1 is required to maintain DNA 
methylation of sites during celular replication. DNMT3a,3b are the de novo 
methyltransferases and can methylate regions of DNA which are unmethylated or as a 
proof reading methyltransferase (Baylin, Jones, 2016). Additionaly, this mechanism of 
de novo methyltransferase activity is key to stably silencing of recently incorporated viral 
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DNA (Meilinger et al., 2009). Recent data suggests the de novo methyltransferases may 
be required for the maintenance of enhancer stability (Rinaldi et al., 2016). DNMT3L has 
no known enzymatic functionality but is known to increase the processivity and thus the 
activity of DNMT3a facilitated methylation of DNA (Holz-Schietinger et al., 2010) The 
inhibition of this group of enzymes has formed the backbone of clinicaly relevant 
epigenetic therapy. 
 
2.3 DNMT Inhibitors 
Three sequence non-specific DNMT inhibitors (Azacitidine, Decitabine, and 
Guadecitabine) are either FDA approved or in phase II clinical trials for hematological 
malignancies. Azacitidine incorporates into both DNA and RNA, while Decitabine and 
Guadecitabine are DNA only incorporators. (Jones et al., 2016). The original application 
of DNMT inhibitors used high doses of these agents and were largely unsuccessful 
(Derissen et al., 2013). The mechanism of action for these agents is the stable 
incorporation of these cytidine analogues into the DNA. DNA methyltransferases then 
interact with these incorporated cytidine analogues forming a covalent bond between 
analogue and enzyme. This leads to the degradation of the enzyme and the formation of 
an abasic site in the genome requiring DNA repair (Stresemann et al., 2008). The 
degradation of DNMTs facilitates the demethylation of the genome either through 
replication dependent DNA demethylation (passive demethylation) or TET mediated 
DNA demethylation (active demethylation) (Chan et al., 2003). Canonicaly speaking the 
activity of DNMTis was thought to be mediated through the reactivation of tumor 
suppressor genes. However emerging data, including the work in this dissertation, 




3. Histone: Acetylation, Acetyltransferase (HATs), Deacetylases (HDACs), and 
HDAC inhibitors 
 
3.1 Histone Deacetylases and Nuclear Repressive Complexes 
As stated above, disregulation of epigenetic regulation of gene expression is a halmark 
of cancer. Aberant silencing of important tumor suppressor or other growth regulatory 
genes by the combination of hypoacetylation and hypermethylation of promoter regions 
results in loss of normal growth control. As such, the histone acetylation state is a critical 
determinant in the transcriptional regulation of important growth regulatory genes, and 
thus HDACs are interesting drug targets that have the potential to reactivate aberantly 
silenced genes in cancer.  
 
3.2 Histone Acetylation 
Histone acetylation is an active process regulated by both the relative abundance and 
localization of histone acetyltransferases (HATs) and nuclear-localized histone 
deacetylases (Ropero et al., 2007). The post-translational modification of acetylation is 
extremely dynamic with a half-life of less than 15 minutes for al modified histones; this 
necessitates continual maintenance of the mark (Barth et al., 2010). Protein acetylation 
induces charge neutralization of histone lysine tails, inducing dissociation of the tails 
from the negatively charged DNA phosphodiester backbone. This removes steric 
hindrance for transcription factor association, thus creating a transcriptionaly permissive 
state at a specified locus (Ropero et al, 2007). 
 
3.3 Histone Deacetylases (HDACs) 
HDACs, or histone deacetylase, enzymes are classified based on celular localization 
and cofactor dependence. The predominant function of this enzyme class is to act as an 
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eraser of one of the marks in the histone code; specificaly, the removal of an acetyl 
moiety from lysines in histone tails. Specificaly, some of the HDACs do function as 
scafolds and readers of the histone code. Thus far, 18 HDACs have been identified to 
date, with 11 HDACs comprising the classical zinc-dependent HDACs, and the 
remaining 7 being the class II NAD-dependent Sirtuins (SIRT 1-7). The presence or lack 
of a nuclear localization signal is critical for determining the celular distribution of the 
classical zinc-dependent deacetylases. These HDACs are subcategorized into 3 distinct 
classes: Class I, Class I and Class IV (Wit, Deubzer, Milde, & Oehme, 2009), (Ropero 
& Esteler, 2007),(Falkenberg & Johnstone, 2014).  
 
Table 1: HDAC Isoforms 
 
 
Class I HDACs 
Class I HDACs are predominantly nuclear localized, consisting of HDACs 1, 2, 3, 
and 8 (Table 1). Class I HDACs have near ubiquitous expression across many disparate 
cel linages (Wit et al., 2009) (Falkenberg & Johnstone, 2014). HDACs 1 and 2 are key 
in terms of histone acetylation regulation as these HDACs form the catalytic core of 
multiple corepressor complexes (Bantschef et al., 2011). These complexes recognize 
methylated CpG DNA through the presence of methyl binding domain proteins such as 
MeCP2 and MBD2 and facilitate the localization of these complexes to areas of CpG 
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island methylation in the genome (Denslow & Wade, 2007; Ebert et al., 2013). HDAC3, 
another critical regulator of histone acetylation, can translocate between the nuclear and 
cytoplasmic compartment, with the primary site of action being the nuclear compartment. 
This HDAC isoform must associate with the NCoR complex to atain a catalyticaly 
permissive conformation, free of repressive chaperones (Codina et al., 2005; Guenther, 
Barak, & Lazar, 2001). HDAC8 has lower enzymatic function, relative to other Class I 
isoforms, but has been implicated in the acetylation of both histone and non-histone 
substrates (Wit et al., 2009). Overexpression of Class I HDAC isoforms 1, 2, and 3 have 
been detected in a wide range of malignancies including prostate, gastric and colon 
cancers. This overexpression is corelated with p21 downregulation resulting in 
dysregulation of the cel cycle (Glozak & Seto, 2007). Critical to the epigenetic therapy 
focus of this review, is the link of HDAC’s 1 and 2 to the DNA methylation processes 
discussed earlier above. These two proteins, as mentioned earlier and further below, 
bind to the DNMT’s as wel as to key complexes that interact with DNA methylation such 
as the MBD’s, the SIN transcription repression complexes, and the NURD complex, 
among others (Rountree et al., 2000, Fuks, et al., 2003, O'Hagan et al., 2008 , Deaton & 
Bird, 2011, (Ahuja et al., 2014; Cai et al., 2014; O'Hagan et al., 2008, Xia et al., 2017) 
 
Class I HDACs 
Class I HDACs function more in terms of non-histone substrate modification and display 
tissue specificity in terms of expression (Verdin, Dequiedt, & Kasler, 2003). Class I 
HDACs are further subseted into two broad categories: Class Ia and Class Ib (Table 
1). Both of these subclasses are zinc dependent and thus subcategorization is based 
more on enzyme activity and the presence of a nuclear localization signal (Wit et al., 
2009) (Falkenberg & Johnstone, 2014). Class Ia HDACs, HDACs 4, 5, 7, and 9, have 
low enzymatic activity and act more as readers of acetylated lysine tails and scafolding 
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than erasers (Bradner et al., 2010). Class Ia HDACs do contain a nuclear localization 
signal, alowing these enzymes to shutle between the nuclear and cytoplasmic 
compartments. Class Ib HDACs, HDACs 6 and 10, actively deacetylate non-histone 
substrates and act to augment protein stability and activation status. This class of 
enzymes lacks a nuclear localization signal and is strictly comprised of cytoplasmic 
deacetylases (Verdin et al., 2003) (Falkenberg & Johnstone, 2014). HDAC6 is a critical 
regulator of the unfolded protein response: in this context, HDAC6 deacetylates HSP90 
and HSP70, alowing for binding of ATP and target proteins (R. Rao et al., 2010). The 
overexpression of HDAC6 has been demonstrated in a wide range of cancers including 
osteosarcoma, AML and ovarian cancers (Glozak & Seto, 2007); (Aldana-Masangkay & 
Sakamoto, 2011). Additionaly, it was elucidated in a study by Lee et al. that HDAC6 is a 
critical determinant of anchorage-independent growth of RAS-transformed MEF cels, 
implicating a crucial role for this HDAC in RAS mediated tumorigenesis (Y. S. Lee et al., 
2008). 
 
Class IV HDAC 
The Class IV HDAC, HDAC11 is a zinc-dependent histone deacetylase whose function 
is largely unknown. Sharing significant homology with both Class I and Class I HDACs, 
HDAC11 does not possess a nuclear localization signal and is thought to act more as a 
cytoplasmic HDAC (Table 1) (Ropero & Esteler, 2007; Wit et al., 2009). 
 
4. Nuclear repressive complexes 
 





As discussed in the Introduction, the Nucleosome Remodeling and Deacetylase complex 
or NuRD nuclear repressive complex provides a link between DNA methylation, histone 
deacetylation and nucleosome remodeling. The interaction of this complex may have 
very special connections to the gene silencing associated with DNA methylation and 
HDACs and for strategies to target abnormalities involving these proteins in cancer (Cai 
et al., 2014). Table 2 provides a summary of the study by Bantschef et al., 2011 which 
elucidated NuRD complex associated chromatin modifiers. The NuRD complex contains 
the core enzymatic components of an HDAC1:HDAC2 dimer, which facilitates the 
deacetylase function of the complex (Bantschef et al., 2011). One of its main 
components, CHD4 is upstream in a DNA damage response for recruiting DNMT's, 
HDAC's and other proteins involved with transcription repressive functions to promoters 
of genes to help initiate and maintain abnormal DNA methylation and gene silencing (Xia 
et al., 2017) functions. Nucleosome remodeling is enabled by the presence of 2 Mi-2 
proteins: CHD3 and CHD4. These SWI/SNF family ATPases compact nucleosome 
structure. Localization of the complex is permited by the presence of methyl CpG island 
binding proteins MBD2 and MBD3, with only MBD2 possessing the functionality of 
methylated DNA recognition (Denslow & Wade, 2007). The NuRD complex provides a 
direct mechanistic link between DNA methylation and alteration of chromatin structure at 
the level of histone modification and nucleosome remodeling (Wong, Guo, & Zhang, 
2014). This model predicts NuRD complex recognition of 5-methylcytosines of the DNA 
through interaction of the complex at the level of MBD2 proteins; after this localization, 
deacetylation of histones and nucleosome remodeling wil facilitate acquisition of the 
transcriptionaly repressive state (Figure 2). The NuRD complex, in conjunction with 
DNA methylation, has demonstrated the propensity to act as a repressive complex in 
colorectal cancer, facilitating the stable repression of tumor suppressor genes such as 











4.2 NCoR and SMRT Corepressor Complex 
 
The Nuclear receptor Corepressor (NCoR) and Silencing Mediator for Retinoid and 
Thyroid receptors (SMRT) corepressor complexes are critical transcriptional repressors 
of nuclear receptors (Wong et al., 2014). This complex interacts with multiple 
deacetylases including HDACs 3, 4, 5, and 7. With regard to deacetylase activity, 
HDAC3 has the highest functionality in this repressor complex, owing to its higher 
intrinsic enzymatic capacity (Bradner et al., 2010). Prior to interaction with the repressor 
complex, HDAC3 is inactive enzymaticaly due to occlusion of the enzyme active site by 
two protein chaperones: Hsc70 and TRiC. The DAD domain of the NCoR-SMRT 
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complex binds HDAC3 at the N terminus, facilitating a conformational change at the C 
terminus. This conformational change expels the protein chaperones from the active 
site, thus activating the HDAC3 enzyme. (W. M. Yang, Tsai, Wen, Fejer, & Seto, 2002) 
(J. Zhang, Kalkum, Chait, & Roeder, 2002) (Codina et al., 2005) (Perissi, Jepsen, Glass, 
& Rosenfeld, 2010). In promyelocytic leukemia (PML) specificaly, it has been 
demonstrated that NCoR occupancy of the retinoic acid (RA) promoter reduces the 
transcriptional induction of RA responsive genes; these cancers are thus immune to the 
diferentiation efects of RA. This provides direct evidence of aberant transcriptional 
regulation by NCoR in driving PML leukemia carcinogenesis (Wong et al., 2014). 
MeCP2, a CpG methylation recognition protein, provides a direct link between the 
NCoR-SMRT complexes and DNA methylation. A study by Ebert et al. 2013, found the 
ablation of the interaction between NCoR and MeCP2 reduced the ability of the methyl 
binding protein to repress transcription (Ebert et al., 2013). The presence of this CpG 
recognition protein is critical to recruit the NCoR-SMRT complex to methylated CpG 
regions to instil repressive chromatin architecture at methylated loci. 
 
4.3 Corepressor of RE1-Silencing Transcription factor (CoREST) Repressor Complex 
 
The CoREST complex is a functional deacetylase and demethylase complex whose 
activity is facilitated by the interaction of lysine-specific demethylase 1 (LSD1) (See 
histone demethylation section below) with an HDAC1:HDAC2 dimer (Table 2) 
(Bantschef et al., 2011). DNA binding and recognition by the CoREST complex is 
enabled by the SANT2 domain of CoREST (Boyer et al., 2002). In this model, the 
SANT2 domain binds the complex to the DNA, and the HDAC1:HDAC2 components of 
the complex create hypoacetylated nucleosomes upstream of LSD1. This facilitates 
substrate recognition by LSD1, which imparts demethylation of H3K4. Furthermore, the 
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association of LSD1 (see below) with the CoREST complex protects the protein from 
degradative processes (Forneris, Binda, Adamo, Bataglioli, & Matevi, 2007; Foster et 
al., 2010; M. Yang et al., 2006). 
The downregulation of E-cadherin is considered an early step in tumorigenesis and a 
potent mediator of the epithelial-to-mesenchymal transition. In a study by Cowger et al., 
a critical role for the CoREST complex was discovered in the facilitation of E-cadherin 
transcriptional repression, thus identifying a direct role for this complex in carcinogenesis 
(Cowger, Zhao, Isovic, & Torchia, 2007). 
H3K4 methylation provides a mechanistic link between the CoREST complex and DNA 
methylation. The presence of the H3K4me3 mark has been demonstrated to act as a 
block for DNMT3L association, while the lack of H3K4 methylation is permissive for the 
association of DNMT3a/b/l (Rose & Klose, 2014). In line with this, a study by Lu et al. 
elucidated that after a transient exposure to DNA methyltransferase inhibitors, 
knockdown of CoREST complex components prevents the remethylation of the MLH1 
promoter (Y. Lu, Wajapeyee, Turker, & Glazer, 2014). This demonstrates a difering but 
equaly important role for the corepressor complex in regulating the epigenome, where 
the repressor complex actively enables the occurence of DNA methylation through the 


















5. HDAC inhibitors 
 
5.1 HDAC Inhibitors: General Mechanism of Zinc Chelators 
 
Current drug development strategies for targeting the classical HDACs center on the use 
of reversible inhibitors to chelate zinc away from the active site of the HDAC enzyme. 
This disrupts the ability of the enzyme to facilitate zinc-dependent substrate coordination 
and nucleophilic atack by water (Lombardi, Cole, Dowling, & Christianson, 2011). The 
general pharmacophore of an HDAC inhibitor folows the schematic of cap-linker-
chelator. Inhibitor specificity is derived from the cap, while the inhibitory functionality is 
based on chelation of zinc away from the active site of the deacetylase (Bantschef et 
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al., 2011; Bradner et al., 2010; Falkenberg & Johnstone, 2014). The general classes of 
HDAC inhibitors are hydroxamic acids, benzamides, cyclic peptides and aliphatic faty 
acids. While the benzamides display Class I specificity in terms of inhibition, the other 
classes of inhibitors are broader spectrum. However, nuanced diferences in isoform 
selectivity can be noted (Bradner et al., 2010; New, Olzscha, & La Thangue, 2012; Wit 
& Lindemann, 2009). Table 3 provides a summary of HDAC inhibitors with associated 
class and phase of clinical development. 
 
Table 2: HDAC inhibitors and associated classifications 
 
 
5.2 Mechanisms of HDAC-Induced Anti-Cancer Efects 
 
HDAC inhibitors are pleiotropic drugs with a wide range of efects, both epigenetic- and 
non-epigenetic-based. HDAC inhibitors induce transcriptional changes in just 2-5% of 
genes, and these changes in isolation do not fuly explain the drug response phenotype 
of cel cycle arest and apoptosis. A wel-known consequence of HDAC inhibition is the 
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induction of p21 transcription; this cyclin-dependent kinase inhibitor has the potential to 
induce G1-S restriction point cel cycle arrest. p21 induction does corelate wel with the 
often observed increase in G1 cel population after administration of high-dose HDAC 
inhibitors, and therefore has at least some phenotypic implications (Gui, Ngo, Xu, 
Richon, & Marks, 2004). 
HDAC inhibitors also induce both caspase-dependent and caspase-independent cel 
death. Caspase 3-induced cel death is dependent on cytochrome c release, a halmark 
of intrinsic apoptosis, while caspase-independent cel death is induced by autophagy 
(Shao et al., 2004). This cel death response has been demonstrated to be at least partly 
dependent on ROS production by HDAC inhibitors. In a study by Bhala et al., a 
hydroxamic acid derivative HDAC inhibitor could induce a 3-fold increase in ROS with 
the apoptosis in this seting determined to be ROS dependent (Bhala et al., 2009). 
 
5.3 HDAC Inhibitor sub classifications 
 
Hydroxamic Acid-Based Inhibitors: Vorinostat and Panobinostat 
 
Vorinostat, or suberoylanilide hydroxamic acid (SAHA), is a hydroxamic acid-based 
HDAC inhibitor with FDA approval for the treatment of CTCL (Table 3) (Mann, Johnson, 
Cohen, Justice, & Pazdur, 2007; Mann, Johnson, He, et al., 2007). Vorinostat displays a 
broad of spectrum of HDAC isoform inhibition, with Ki values measuring in the low 
nanomolar range for HDACs 1, 2, 3 and 6, a Ki of 480 nM for HDAC8 and a Ki of 3.6 uM 
for HDAC4; no measurable inhibition could be ascertained for the remaining HDACs 
(Bradner et al., 2010). Vorinostat is dosed at 400 mg daily for the treatment of CTCL 
patients who have failed two prior systemic therapies. A phase I trial in refractory CTCL 
patients noted a 31% response rate to Vorinostat (Mann, Johnson, Cohen, et al., 2007; 
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Mann, Johnson, He, et al., 2007). Panobinostat is a very potent, broad-spectrum 
hydroxamic acid HDAC inhibitor, displaying Ki values in the low nanomolar and 
picomolar range for HDACs 1, 2, 3 and 6. Relatively high potency was also noted for 
HDACs 4, 5 and 8, with Ki measurements of 550 nM, 80 nM and 105 nM, respectively 
(Bradner et al., 2010). Panobinostat has been deployed clinicaly in combination with the 
proteasome inhibitor Bortezomib, resulting in noted drug synergy. The mechanism of this 
synergy is based upon HDAC6-mediated deacetylation of HSP90 and the subsequent 
augmentation of the unfolded protein response (R. Rao et al., 2010). The perturbation of 
this unfolded protein response is most acutely toxic in the immunoglobulin-secreting 
environment of multiple myeloma. In the PANORAMA trial, the combination of 
Panobinostat + Bortezomib + Dexamethasone resulted in an increase of progression-
free survival from 8.1 months in the Bortezomib + Dexamethasone group to 12 months 
in refractory myeloma patients (Richardson et al., 2016; San-Miguel et al., 2013). 
The FDA has granted accelerated approval to another hydroxamic acid derivative, 
Belinostat, (Table 3) for the treatment of relapsed or refractory Peripheral T Cel 
Lymphoma, based on the results of a phase I trial (H. Z. Lee et al., 2015). The FDA 
mandates that a phase II trial be conducted to explore Belinostat in combination with 
Cyclophosphamide, Hydroxydaunorubicin, Oncovin, and Prednisone (CHOP) vs. CHOP 
alone as a part of this accelerated approval. 
Thus far, histone deacetylase inhibitors have demonstrated much promise for the 
treatment of hematological malignancies, but the results in solid malignancies have been 
disappointing to date. 
 




An exception to the lack of eficacy, to date, for HDAC inhibitors in solid tumors may be 
Entinostat, which is gaining traction for the treatment of solid malignancies. Entinostat, or 
MS275, a benzamide-based HDAC inhibitor, has received breakthrough therapy status 
for advanced ER+ breast cancer and has been deployed clinicaly for a wide range of 
malignancies (Table 3). As a benzamide-based inhibitor, Entinostat displays selective 
inhibition of class I HDACs with Kis for HDACs 1 and 3 of 22 nM and 360 nM, 
respectively (Bradner et al., 2010). In a phase I clinical trial which compared the eficacy 
of 25 mg Exemestane daily with placebo or 5mg Entinostat weekly in ER+ breast cancer, 
the addition of Entinostat led to a significant increase in progression-free survival and 
overal survival (Yardley et al., 2013). 
 
Cyclic Tetra Peptide-based Inhibitor: Romidepsin 
Romidepsin, or FK228, is a cyclic tetrapeptide-based HDAC inhibitor with FDA approval 
for the treatment of CTCL and Peripheral T Cel Lymphoma (PTCL) (Table 3). The FDA 
recommended dose and schedule is 14 mg/m2 IV on days 1, 8 and 15 of a 28-day 
schedule. A phase I trial noted an overal response rate of 34%, with a durable 
response of 13-15 months in refractory CTCL patients (S. F. Jones et al., 2012; M. Kim, 
Thompson, Wenger, & O'Bryant, 2012). Romidepsin is a very potent HDAC inhibitor with 
biochemical Ki’s in the picomolar range for al class I HDACs. High potency was also 
noted against HDACs 4 and 6, with Ki’s of 20.5 nM and 9.5 nM, respectively (Bradner et 
al., 2010). 
 
5.4 Biomarkers of Response to HDAC Inhibition and Prognostic Indications 
 
The search for prognostic indicators of histone deacetylase inhibitor activity and patient 
response has been thus far rather dificult. The canonical and most deployed marker of 
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histone deacetylase inhibitor activity is augmentation of histone acetylation status; while 
potentialy useful, it has been shown to not correlate with response to the therapeutic 
(Prince, Bishton, & Harrison, 2009). The induction of p21 has also been deployed as a 
marker of drug activity, due to its near ubiquitous induction in the presence of histone 
deacetylase inhibition (Stimson & La Thangue, 2009). But like acetylation augmentation, 
p21 induction is not always correlated with response. 
A potential prognostic indicator for response to histone deacetylase inhibitors may lie in 
the detection of a deregulated proteasome pathway. In a study by Fotheringham et al., a 
genome-wide loss-of-function screen in U2OS cels identified HR23B, a ubiquitin 
domain-containing protein, as a predictive biomarker for HDAC inhibitor response. 
Specificaly, protein levels of HR23B were found to corelate directly with the sensitivity 
of cels to undergo HDAC inhibitor induced apoptosis, in this seting. Additionaly, in a 
later study by Kim et al., this same marker was found to drive sensitivity of CTCL to 
HDAC inhibitors in clinical samples with a positive predictive value of 71.7% noted 
between HR23B protein abundance, as discerned by immunostaining of CTCL biopsies, 
and sensitivity to SAHA (Fotheringham et al., 2009; Khan et al., 2010). 
In summary, although the precise mechanisms by which HDAC inhibitors interfere with 
tumor growth have not yet been fuly elucidated, encouraging clinical results in specific 
cancers with multiple classes of these inhibitors suggest a promising future for their use. 
Future studies must elucidate HDAC inhibitor sensitivity biomarkers to more accurately 
target patients for HDAC inhibitor-based therapies. Furthermore, the question of which 
HDACs should be inhibited and what schedule of drug should be used remains open 
and most likely wil be mutational and lineage dependent. 
 
6. Potential synergy between combination epigenetic therapy and immune 
checkpoint for the treatment of refractory, recurrent NSCLC 
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An early indication of the potential synergy between DNMTi, HDACi and immune 
checkpoint therapy was observed in a smal clinical cohort of refractory, recurrent 
NSCLC patients (Juergens et al., 2011). In this trial of combination Azacitidine plus 
intermitent MS-275, 2 patients displayed efacacious responses to combination 
epigenetic therapy alone with durable 14 month complete response and an 8 month 
partial reponse noted. A total of 19 epigenticaly treated patients received subsequent 
systemic therapies and 3 of these displayed efacacious reponses to anti-PD1 therapy 
with a noted regression in target lesion size from 30 to 60%. While these data provided 
evidence that NSCLC lesions may respond to combination epigenetic and immune 
therapies, the derivation of how this combination truly worked or markers predictive of 
reponse were not elucidated. 
 
I. NSCLC epithelial specific response to combined epigenetic therapy 
 
1. Introduction 
Identifying rational combinations to augment anti-tumor immunity and increase the 
response to immune checkpoint therapy represents a major chalenge for the field. 
Durable responses were observed in patients with NSCLC who were initialy treated with 
a DNA methyltransferase inhibitor (DNMTi) combined with intermitent histone 
deacetylase inhibitor (HDACi) folowed by immune checkpoint therapy (Juergens et al., 
2011). Combination epigenetic therapy regimens most commonly utilize DNMTi’s in 
combination with HDACi’s on the premise that the later can enhance re-expression of 
abnormaly silenced genes mediated by abnormal, gene promoter DNA methylation 
(Cameron et al., 1999; Jones et al., 2016). However, litle atention has been paid to 
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examining the specific pharmacologic features of HDACi, optimal dosing strategy, and 
underlying mechanisms mediating maximal synergy with DNMTi’s. The zinc chelating 
HDACi’s are comprised of 3 major classes: benzamide, hydroxamic acid, and cyclic 
tetrapeptides (Bradner et al., 2010; Falkenberg and Johnstone, 2014; Rasheed et al., 
2007; Zahnow et al., 2016). Benzamide class HDACi’s target class I HDAC isoforms, 
while hydroxamic acid class HDACi’s target both Class I (HDACs 1,2,3) and Class Ib 
(HDAC6), although diferences in isoform targeting can be noted (Bradner et al., 2010).  
We have earlier shown that low-doses of DNMTi impart durable changes in both 
genome-wide DNA methylation and transcriptome while avoiding acute cytotoxicity (Tsai 
et al., 2012). Additionaly, we and others have discovered that DNMTi’s can induce an 
epithelial immune signature for NSCLC and other cancers (Li et al., 2014; Moreno-Bost 
et al., 2011; Oi et al., 2009; Weiser et al., 2001; Wrangle et al., 2013). A key mediator of 
this signaling, is a cytoplasmic, double stranded RNA (dsRNA) mediated interferon 
response induced through the activation of endogenous retrovirus (ERV) transcription 
(Chiappineli et al., 2015; Roulois et al., 2015). How the distinct classes of HDACis 
contribute to enhancing immune therapy specificaly is unknown. 
Herein, testing individual HDACi’s based on both their isoform specific Ki’s and 
pharmacokinetic parameters, enabled the best pairing of these agents with Aza for 
achieving anti-tumor efects, which include immune responses. 
 
2. Materials and methods 
Cel lines and cel culture: 
Non smal cel lung cancer cel lines used in the study were obtained from ATCC. The 
cels were cultured in RPMI1640 media (Corning) containing FBS ( Hyclone) at 10% v/v. 
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Cels were maintained at 37°C in the presence of 5% CO2. Cels were passaged every 
3 days. Human Non Smal Cel Lung Cancer cel lines: NCI-H1755 (female), NCI-H520 
(male), NCI-H1650 (male), NCI-H1975 (female), NCI-H441 (male), NCI-H661 (male), 
NCI-H596 (male), HCC4006 (male), NCI-H1703 (male), NCI-H838 (male), NCI-H2170 
(male), NCI-H1792 (male), NCI-H460 (male), NCI-H23 (male), A-549 (male), NCI-H1299 
(male), HCC827 (female) 
 
In Vivo Mouse Studies: 
Xenograft studies in NOD/SCID mice : 
We used male NOD-SCID mice (5-6 weeks old) for these studies. Mice were bred and 
housed at the Johns Hopkins Animal care facility. Al animal experiments were approved 
by the Johns Hopkins Animal Care and Use Commitee. Al animal care and protocols 
folowed were in accordance with guidelines of the institutional Animal Care and Use 
Commitee (IACUC). Mice were injected subcutaneously in the flank with 2.0 x 105 viable 
cels for H1299 and 5.0 x 104 
viable cels H460 cels in 0.2 mL of RPMI with Matrigel (1:1). Drug treatments were started 
10 days post injection for H460 and 14 days post injection for H1299, when palpable 
tumors could be discerned and continued as indicated in the figure. Mice were treated with 
the dosing schedules shown in (Figure 7A). Treatment was continued for the entire 
duration of the study and mice were sacrificed when tumors size exceeded 2000mm3. 
Tumor volume determined by measurements obtained from digital caliper and calculated 
as V= 0.5(LxWxH). 
 
PDX mouse model: 
A PDX mouse model (TM00302) was obtained from Jackson Laboratories. This model 
was derived from metastatic lung adenocarcinoma in a female patient with the folowing 
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mutations KRAS G12D; KDR Q472H, TP53 R158L. The tumor was harvested from a JAX 
provided donor mouse mouse and sectioned into 2mm3 fragments. These fragments were 
then implanted subcutaneously in the flank of male NSG mice (5-6 weeks old). Once 
implanted tumors were papable, mice were randomized into three treatment groups and 
dosed as depicted in Figure S7A. Mice were treated for the duration of the study and at 
culmination of treatment mice were sacrificed. Tumors were excised from the animals and 
weighed as a measure of disease burden. 
 
Drug Reagents: 
Azacidine (Sigma) was dissolved in PBS at 500uM (in vitro) and 7.1 mg/mL (in vivo), 
aliquoted, and stored at -80C for single use. ITF-2357 (Apexbio) was dissloved in DMSO 
to concentrations of: 1mM, 500uM, 250uM, 100uM, 50uM and 25uM (in vitro) and 
50mg/mL (in vivo), aliquoted and stored at -20C. MS-275 (Syndax) was dissloved in 
DMSO to concentrations of: 2.5mM, 1mM, 500uM, 250uM, 125uM (in vitro) and 
50mg/mL (in vivo), aliquoted and stored at -20C. MGCD0103 (Apexbio) was dissloved in 
DMSO to concentrations of: 1mM, 500uM, 250uM, 100uM, 50uM and 25uM (in vitro) and 
10mg/mL (in vivo), aliquoted and stored at -20C. RGFP996 (Apexbio) was dissloved in 
DMSO to concentrations of: 10mM, 5mM, 2.5uM, 1uM, 500uM and 100uM (in vitro), 
aliquoted and stored at -20C. Tubastatin A (Apexbio) was dissloved in DMSO to 
concentrations of: 10mM, 5mM, 2.5mM, 1mM, 500uM and 250uM (in vitro), aliquoted 
and stored at -20C. Vorinostat (Cel signaling) was dissloved in DMSO to concentrations 
of 300uM (in vitro), aliquoted, and stored at -20C. Puromycin (Sigma), dissolved in PBS 
at 1mg/mL, aliquoted and stored -20C. 
 
Azacitidine drug treatments: 
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Cel lines were plated at the folowing densities for Azacitidine treatments per T75 flask: : 
NCI-H1755 (2.0*105), NCI-H520 (2.0*105), NCI-H1650 (2.0*105), NCI-H1975 (1.0*105), 
NCI-H441 (2.0*105), NCI-H661 (2.0*105), NCI-H596 (2.0*105), HCC4006 (2.0*105), NCI-
H1703 (2.0*105), NCI-H838 (1.0*105), NCI-H2170 (2.0*105), NCI-H1792 (1.0*105), NCI-
H460 (1.0*105), NCI-H23 (2.0*105), A-549 (1.0*105), NCI-H1299 (1.0*105), HCC827 
(2.0*105) .Alowed to adhere for 24 hours before the onset of treatment. Cels were 
treated with 500uM Azacitidine diluted 1:1000 or PBS vehicle in complete RPMI1640 
media every 24 hours for the indicated treatement duration. Drug treatments with HDACi 
are assay specific and are detailed in the relevant sections. 
 
Cel Viability Assays (MTS colorimetric): 
Cels treated as described in Azacitidine treatment section, were trypsinized, 
enumerated, and assesed for viability by trypan blue exclsuion assay. Equal numbers of 
viable cels were plated in 96 wel plates at the folowing densities per wel, in technical 
triplicate: : NCI-H1755 (2.0*103), NCI-H520 (2.0*103), NCI-H1650 (2.0*103), NCI-H1975 
(1.0*103), NCI-H441 (2.0*103), NCI-H661 (2.0*103), NCI-H596 (2.0*103), HCC4006 
(2.0*103), NCI-H1703 (2.0*103), NCI-H838 (1.0*103), NCI-H2170 (2.0*103), NCI-H1792 
(1.0*103), NCI-H460 (1.0*103), NCI-H23 (2.0*103), A-549 (1.0*103), NCI-H1299 (1.0*103), 
HCC827 (2.0*103) . Cels were alowed to adhere for 24 hours in the presence of 
complete media prior to the onset of treatment. Adhered cels were incubated with 100uL 
drug supplemented media every 3 days, treated with DMSO(vehicle) at .1% or the 
folowing drugs/concentrations standarized to .1% DMSO final concentration. ITF-2357: 
25nM, 50nM, 100nM, 250nM, 500nM, 1uM; MGCD0103: 25nM, 50nM, 100nM, 250nM, 
500nM, 1uM; RGFP996: 250nM, 500nM, 1uM, 2.5uM, 5.0uM and 10uM; Tubastatin A: 
250nM, 500nM, 1uM, 2.5uM, 5.0uM and 10uM; MS-275: 125nM, 250nM, 500nM, 1uM, 
2.5uM. Treatments were applied for a period of 5 days, afterwhich, MTS colorimetric 
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assay (promega) was conducted. MTS reagent was diluted 20uL per mL in complete 
and vortexed to ensure the resultant solution was homogenous. Drug treated was gently 
removed from treated cels by multichannel pipete and replaced MTS supplemented 
media. Cels were incubated in 37C incubator to alow the colorietric reaction to occur. 
After incubation 490nm absorbance was read using the BioRad iMark microplate reader 
for media+MTS, vehicle treated+MTS and drug treated+MTS cels. Absorbance values 
were imported to Graphpad prism. Data were normalized the vehcicle treated cels for 
both mock and Aza treated condtion. Drug doses were log transformed. These 
normalized, log transformed data were analyzed by 4 parameter nonlinear regreesion to 
generte log dose response curves for each cel line and drug condition and 
determination of drug efect at dose. The resultant dose repsonse curves are a 
representation of these data, with the indicated biolofical replicates being a represention 
of the mean for each condtion. These dose response data were utlitized for drug synergy 
analysis (Compusyn). The fractional efect data for each drug condtion were imported for 
drugs both alone and in combination with Aza. These data were anayzed and used to 
generate combination index output as an indicator of drug synergy. 
 
BrdU Cel Prolifertion Assay, colorimetric ELISA: 
Cels were plated in technical triplicate in 96 wel fomat at the densities described in the 
Cel viabilty section. Vehicle or Aza treated cels were alowed to adhere for 24 hrs prior 
to the onset of treatment. Cel were subsequently treated with the folowing inhibtiors for 
3 days. MGCD0103: 200nM, ITF-2357: 100nM, Tubastatin A: 1uM, RGFP996: 2uM. On 
day 3 of treatment, Stock Brdu (Calbiochem BrdU Cel Proliferation Assay) was diluted 
1:1000 in complete media and added to 100uL of drug treated media. Cels were 
incubated with BrdU at 37C for 5 hours to alow for DNA synthese based incorporation. 
The remainder of protocol was carried out as decribed in Calbiochem protocol, with the 
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lot specifc 1:2400 dilution of secondary antibody. 450nm absorbance values derived 
from ELISA were measured using the Biorad iMark plate reader. The triplicate 
measurements per condition were imported to graphpad prism and the data background 
subtracted, normalized to vehicle treated control to generate the normalized proliferation. 
Error bars depicted as SEM between the means of experimental replicates, after 
computing the mean of technical triplicates. Statistical signifcance is the result of two 
way anova conducted between the experimental conditions depicted. 
 
Gene expression analysis by microaray: 
RNA expression were conducted by microaray for the conditions descibed in the 
relevant figures. The R/Bioconductor package limma was used to process expression 
data. Within- and between-array normalizations were performed using the loess and 
aquantile methods, respectively. The normexp option was used for background 
correction. Raw files read in using the read.maimages function. Log2 fold change in 
transcription for drug treated conditions over mock treated was obtained for each sample 
at each time point studied. Ranked lists of log2 fold change were analyzed using Gene 
Set Enrichment Analysis (GSEA) by the Broad Institute and data packages 
(Subramanian et al., 2005). Pathways enriched with a false discovery rate less than 0.25 
were selected with cutof of 2.0 normalized enrichment score in human studies. Median 
absolute deviation analysis of Log2 fold change transcription data were obtained using 
Morpheus program (Broad). Top 500 genes were selected and depicted as heatmap 
representative of minimum to maximum value ranking for each gene across cel lines 
and conditions. 
 
DAVID analysis of median absolute deviation derived genes (KEGG Pathways): 
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Top 500 genes derived by median absolute deviation analysis were obtained as 
described in Gene expression by microarray methods section and were analyzed for 
KEGG Gene Ontology (GO) enrichment using the DAVID Bioinformatics resources 
database (Huang da et al., 2009a, b). Only categories that were below the DAVID p 
value of .05, and containing at least 5 genes per pathway are reported. 
 
ERV absolute quantitative real time PCR (qPCR): 
Eleven codogenic and partialy codogenic ERV envelope (env) gene families (see Figure 
3 and Figure S4 for ERV env genes used in this investigation), one ERV gag (ERV-W5) 
and two ERV pols (ERVFXA34, erv9-1) were quantified using qPCR and have been 
previously described (Chiappineli et al, 2015). Additionaly, some of these ERV primers 
could potentialy hybridize with other ERV transcripts among the ERV family members, 
e.g. the ERV-K env primers could hybridize with 8 transcripts derived from ERV-K102 
(1q22), -107 (5q33.3), -108 (7p22.1), -109 (6q14.1), -113 (19p13.11), -115 (8p23.1), -
17833 (19q12), -74261 (12q14.1) according to sequence alignments (Chiappineli et al, 
2015). 
The qPCR methodology detecting the ERV genes has been previously described 
(Chiappineli et al, 2015). Briefly, ERV genes were amplified by qPCR from 40 ng of cel 
line cDNA with SYBR-green technology and then analyzed with an ABI7300 (ABI, 
Darmstadt, Germany). Expression values were calculated as molecules per ng total 
RNA using a standard curve of each cloned gene determined by real time PCR and 
calculated as mean +/- SEM. TBP and beta-actin were used as housekeeping genes 





qPCR methodology for detecting IFNα/β related genes (ISG15, OASL1, HLA-A, HLA-B) 
diferential expression was conducted on 20ng of cel line cDNA with SYBR green 
technology. Expression values were calculated as fold change over mock by delta-delta 
ct. Beta-actin was used as housekeeping gene for normalization of NSCLC cel line 
expression. 
 
Taqman microfluidic genecard: 
1ug of total RNA was used for cDNA reaction and diluted to 50uL total volume in 
molecular grade water. Diluted cDNA was combined with 50uL of Taqman universal 
PCR mastermix and loaded onto a Taqman microfludic genecard with the folowing 
primer/probe sets preloaded: IRF7, IFI27, STAT1, IFNB1, MX1, OASL, IFI6, beta actin, 
TBP. Expression values were calculated as fold change over mock by delta-delta ct. 




Protein was extracted by 4% SDS mediated lysis, folowed by processing of lysates 
through homogenizer column (Omega). Protein concentrations were estimated by BCA 
(Pierce Biotechnology). Lysates were processed using PAGE with 4-12% Bis-Tris BOLT 
gel (Life Technologies) and transferred to PVDF membrane (Milipore). Membranes were 
blocked in 10% milk/TBST and immunobloted with the folowing antibodies.: Rabbit 
monoclonal anti-Acetyl α Tubulin (Cel Signaling, 1:1000), Rabbit monoclonal anti-
Acetylated Histone 3 (Cel Signaling, 1:1000), Rabbit polyclonal anti-Histone H3 (Cel 
Signaling, 1:1000), Rabbit polyclonal anti-DNMT1 (Sigma Aldrich, 1:2000), Mouse 
monoclonal anti-β-Actin (Sigma Aldrich, 1:10000). The loading control antibodies (anti-β-




DNMT1 Knockdown Cel Viability Assay: 
DNMT1 knockdown was initated, see refernce for sequence (Cai et al., 2017) and 
control vector shGFP 5′- GCAAGCTGACCCTGAAGTTCAT3-3′. Clonal selection was 
initated with puromycin selection. Selected clones were plated at cel densities, treated 
and analyzed as described in Cel viabilty Assay section of methods. Error bars are 
representative of mean +/- SEM between experimental replicates. 
3. Results 
Combination Aza + ITF-2357 induces drug synergy when applied to human NSCLC  
Selection of HDACi’s was instituted by pairing these agents with low-dose (500 nM) Aza. 
Clinicaly relevant HDACi’s (ITF-2357, MGCD-0103, MS-275) were selected and paired 
with Aza based on their known pharmacokinetic parameters (cmax and half-life) and 
enzymatic Ki’s against key HDAC isoforms (Table 3) (Bradner et al., 2010; Falkenberg 
and Johnstone, 2014; Furlan et al., 2011; Gore et al., 2008; Rasheed et al., 2007; Ryan 
et al., 2005; Zahnow et al., 2016). 
 




Compound ~cMax ~Half-life HDAC Ki uM
1 2 3 6
ITF-2357 300nM 7 hrs. .002 .003 .003 .0042
SAHA 1.0uM 1.5-2 hrs. .0013 .0016 .005 .0016
MGCD0103 600nM 9.9 hrs. .009 .034 .265




We initialy examined the efect of sequential Aza + HDACi on cel proliferation across a 
panel of 16 cel lines representing the diverse oncogenotypes of NSCLC (Figures 5 and 
6). These data revealed that the antiproliferative efect of this treatment regimen 
correlated with the subtype and mutational status of the NSCLC cel line queried. The 
hydroxamic acid class HDACi (ITF-2357) in combination with Aza demonstrated the 
most potent antiproliferative phenotype. Among our four most responsive cel lines, three 
were RAS mutant subtype. Therefore, we selected these cel lines for further studies of 
therapeutic scheduling and HDAC isoform targeting delineation. Using a comparative 
analysis, wherein, Aza and ITF-2357 are both sequentialy and concurrently employed 
(Figure 4), only the former schedule induces both synergy and robust potentiation of 






Figure 4: Concurrent and sequential Aza + HDACi treatment schemas 
In vitro treatment schema for sequential and concurrent application of Aza and/or HDACi 
to NSCLC cel lines. (D) Log dose response curve of MTS data for H460 cels treated 
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concurrently with Aza and variable concentrations of ITF-2357 (day 5, data are mean ± 
SEM, n=3). 
 
Figure 5: Composite representation of ITF-2357 IC50 through the application of 
sequential Aza + ITF-2357 
Composite representation of ITF-2357 IC50 as determined by four parameter dose 
response analysis in the presence of mock or 500nM Aza pre-treatment. Individual dose 






































































































































































































































































































































































































































































Figure 6: Sequential Aza + HDACi NSCLC cel line dose response data for 
benzamide and hydroxamic acid HDACis 
 
Log dose response curves of MTS data from screen of NSCLC cel lines treated 
sequentialy with either vehicle or 500nM Aza folowed by the HDAC inhibitors indicated 





























































































































































































































































































































































































































































Figure 7: A549 and H460 dose response and combination index of sequential Aza 
+ ITF-2357 in comparison to H460 concurrent Aza + ITF-2357 
(A) Sequential treatment (mock or 500nM Aza) ITF-2357 log dose response curves for 
growth inhibition of A549 and H460 cels (day 11, n=5, Data represented as mean ± 
SEM). (B) Combination index (CI) plots for sequential application of Aza + ITF-2357 in 
A549 and H460 cels (n=5). (C) Log dose response curve of MTS data for H460 cels 
treated concurrently with Aza and variable concentrations of ITF-2357 (day 5, data are 



















































We thus used this schema of sequential treatment in our further studies. To delineate 
the enhanced anti-proliferative efect of ITF-2357 over the others we next tested the 
function of the individual HDAC isoforms in the Aza priming response to HDACi. We find 
through the application of HDAC isoform specific inhibitors, an Aza induced priming to 
both class I and Ib targeting HDACis (Figures 8 and 9). These data suggest the 
observed Aza + ITF-2357 antiproliferative phenotype to be the result of broader targeting 











Figure 8: Aza imparts sensitization to diferential isoform specific HDAC inhibitors 
when applied in a sequential manner 
 
Sequential treatment (mock or 500nM Aza) MS-275, RGFP996 (HDAC3i), Tubastatin A 
(HDAC6i) log dose response curves for growth inhibition of A549 and H460 cels (day 
11, n=3, Data represented as mean ± SEM). 




















































































































































Figure 9: The application of HDAC isoform inhibitor combinations potentiates the 
activity of HDACis especialy in Aza primed NSCLC cel lines 
 
Sequential treatment (mock or 500nM Aza) with MS275 plus either RGFP996 or 
Tubastatin A drug dose response matrix for growth inhibition of A549 and H460 cels 











































































































As a further characterization of the antiproliferative efects of Aza in combination with 
HDACi, we deployed equal molar concentrations of MS-275 and ITF-2357 and assessed 
cel proliferation specificaly. In agreement with the previous data, we find 100nM ITF-
2357, a concentration roughly one-third cmax, (Furlan et al., 2011) demonstrated a more 
robust inhibition of proliferation than 100nM MS-275 (Figure 11A). We next sought to 
define the contribution of individual HDAC isoforms to the antiproliferative efect noted 
from 100nM ITF-2357. To accomplish this end, we first determined equivalent doses 
based on isoform pharmacodynamic targets, these being, histone acetylation for 
HDAC1,2 and tubulin acetylation for HDAC6 (Asthana et al., 2013; Fournel et al., 2008; 
Khan et al., 2008). The resulting equivalent doses were 200nM MGCD0103 and 1000nM 
Tubastatin A to mimic 100nM ITF-2357 (Figure 10). Selection of 2000nM RGFP996 for 
HDAC3 inhibitor was based on extrapolation of Ki, due to lack of known 
pharmacodynamic markers for these isoform (Malvaez et al., 2013) These normalized 
doses of HDAC isoform specific inhibitors identify HDACs 1, 2 and 3 as key arbiters of 










Figure 10: HDACi pharmacodynamic control immunoblot 
Evaluation of pharmacologic targets of HDAC1/2: histone acetylation and for HDAC6, 
tubulin acetylation by immunobloting in A549 cel line. Histone 3 and β-Actin used as 
loading controls. Drug and drug concentrations are indicated in the figure. (24-hour 















Figure 11: Nuclear HDAC isoforms elicit cel cycle inhibition in combination with 
Aza 
 
(A) Normalized BrdU percent positivity for Aza +/- 100nM MS-275 or 100nM ITF-2357 
(day 9, n=4 (MS-275), n=6 (ITF-2357)). Data are presented as mean ± SEM. * p value < 
0.05 relative to mock, # p value < 0.05 relative to Aza + MS-275 (B) Normalized BrdU 
percent positivity for mock or Aza treated cels in combination with the indicated HDACi’s 

























































































Additionaly, to elucidate the specificity of Aza priming to HDACi we deployed shRNA 
mediated DNMT1 depletion, the major pharmacodynamic target of Aza (Cai et al., 2014). 
We observe potent augmentation of the HDACi anti proliferative efect when utilized in 
combination with DNMT1 depletion (Figure 12A and 12B). 
 
 
Figure 12: DNMT shRNA knockdown phenocopies Aza priming to nuclear isoform 
targeting HDACi 
 
(A) Immunobloting for DNMT1 in A549 and H460 cels infected with empty vector or 
shDNMT1 vector. β-Actin used as loading control (day 5, n=2) (B) Log dose response 
for A549 and H460 cels infected with empty vector or shDNMT1 vector and treated with 








Finaly, we tested the eficacy of sequential Aza + HDACi in vivo using immune-
incompetent mice. We observed significant reduction of tumor burden across 3 xenograft 
models, two for established NSCLC cel lines and one using a KRAS, KDR, TP53 mutant 
primary patient derived xenograft (PDX) model when utilizing Aza + ITF-2357 (Figures 
13A, 13B, 13C). The combination of Aza + MS-275 did not have significant eficacy in 
the H460 xenograft model, the most sensitive cel line tested, at the doses used in our 
study (Figure 13A). Aza + MGCD0103 achieved significant eficacy in H460 xenografts 

































































































Figure 13: Combination Aza + HDACi displays eficacy in multiple NSCLC 
xenograft models 
 
(A and B) Mean volumes of tumor xenografts obtained from NOD-SCID mice 
subcutaneously injected with H460 cels (A) or H1299 cels (B) and treated with the agents 
as indicated in the figure. (Data are presented as mean ± SEM, n=5). (C) Tumor weights 
for patient derived xenografts treated with the agents as outlined in the figure (28 days of 
treatment duration, data are presented as mean ± SEM, n=6 mock; n=7 Aza + ITF-2357). 
(D) Average volumes of tumor xenografts obtained from NOD-SCID mice subcutaneously 
injected with H460 cels (Day 0 equals onset of treatment, data are mean ± SEM, n=4 
mock, n=5 Aza + MGCD0103). (E) Tumor weights for patient derived xenografts obtained 
from NSG mice and treated with the agents as outlined in the figure, mock data are also 
presented in Figure 1H (28 days of treatment duration, n=6 mock n=7 Aza + MGCD0103, 
data are mean ± SEM) 














Efects of the drug combination paradigm on the transcriptome in NSCLC lines 
 
Assessment of drug combination induced efects on gene expression yields important 
insight for signaling pathway alterations that may relate to eventual clinical eficacy. The 
combination epigenetic treatment induces an increase in diferential gene expression 
relative to HDACi mono-treatment conditions, with a clear advantage noted from the 
application of Aza + ITF-2357 (Figure 14A). Clustering of top 500 diferentialy 
expressed genes shows a divergence between HDACi mono-treatment and Aza 
containing regimens (Figure 14B). DAVID pathway analysis revealed the most 






















Figure 14: Combination Aza + HDACi potentiates diferential gene expression over 
mono treatments alone, with a focus on Immune, Metabolism and MYC related 
genes 
 
(A) Quantitation of diferentialy expressed genes (cutof Log2 fold change over mock > 
0.5) for each treatment condition. (B) Unsupervised hierarchical clustering of relative 
RNA expression by median absolute deviation (MAD). RNA expression is Log2 fold 
change over mock, blue to red color gradation is based on the ranking of each condition 
from minimum (blue) to maximum (red). The top 500 genes are depicted. (C) DAVID 
analysis of the top 500 MAD genes using KEGG gene ontology. 
Above data are derived from microaray analysis of RNA from cels treated with 500nM 






Gene Set Enrichment Analysis (GSEA) identified three significantly induced pathways by 
combination epigenetic treatment, two of which are related to immune signaling (Figure 
15A). The interferon alpha-beta (IFNα/β) signaling pathway was the most prominent of 
these altered pathways (Figure 15C). Comparative analysis of combination epigenetic 
treatment downregulated pathways by GSEA revealed a conserved cel cycle repression 
signature across the drug combinations tested with a noted advantage for Aza + ITF-
2357 (Figure 15B). The above transcriptional downregulation of cel cycle related 
pathways elicited by combinatorial epigenetic treatment matches with the observed 
























Figure 15: Aza + HDACi significantly imparts alteration of immune and cel cycle 
related genes sets 
 
(A) Venn diagrams quantitating GSEA derived overlapping and unique pathways 
induced by combination treatment in at least 3 cel lines with the respective HDACi. 
(NES > 2.0, FDR < 0.25) and venn diagram of pathways commonly upregulated by 
combination treatment with Aza and the respective HDACi. (B) Venn diagrams 
quantitating GSEA derived overlapping and unique pathways downregulated by 
combination treatment in at least 3 cel lines with the respective HDACi. (NES < 2.0, 
FDR < 0.25) and venn diagram of pathways commonly down regulated by combination 
treatment with Aza and the respective HDACi. (C) GSEA enrichment plots for top 
upregulated pathway (Interferon αβ) folowing combination epigenetic treatment with the 
indicated HDACi. (D) GSEA enrichment plots for top downregulated pathway (DNA 
replication) folowing combination epigenetic treatment with the indicated HDACi. Above 
data are derived from microaray analysis of RNA from cels treated with 500nM Aza, 












2.3 The potential of combinatorial epigenetic treatment to stimulate specific immune 
related genes 
 
A primary goal for combined epigenetic therapy is to increase the eficacy of immune 
checkpoint and other immunotherapies. We found the combination of Aza + ITF-2357 to 
be the most efective relative to other conditions tested in terms of induction of IFNα/β 
pathway related genes, including those associated with antigen presentation (Figures 



























































































































Figure 16: IFNα/β related genes are a conserved target of Aza + HDACi 
(A) Heatmap of relative RNA expression for IFNα/β signaling pathway core enriched 
genes for indicated cel lines (microaray, day 8, 500nM Aza, 100nM MS275, 100nM 
ITF-2357). (B) Quantification of IFNα/β pathway core enriched genes diferentialy 
expressed by the indicated conditions (microaray, day 8, 500nM Aza, 100nM MS275, 
100nM ITF-2357; diferential gene expression cutof Log2 fold change over mock > 0.5). 
(C) Expression of Interferon stimulated genes induced by Aza and/or the indicated 








To demonstrate whether this eficacy of immune gene induction by Aza + ITF-2357 was 
potency or isoform targeting based, we used isoform specific HDACi at concentrations 
mimicking 100nM ITF-2357. We observe the inhibition of HDAC1, 2 (MGCD0103) and 
HDAC6 (Tubastatin A) in combination with Aza induces IFNα/β pathway related genes, 
including antigen presentation, while HDAC3 (RGFP996) specific inhibitors demonstrate 


























Figure 17: Inhibition of HDAC 1,2,6 isoforms increases Aza induced augmentation 
of IFNα/β related genes 
 
(A and B) Expression of viral defense gene subset of IFNα/β pathway (PCR genecard, 
day 8, 500nM Aza, 100nM ITF-2357, 200nM MGCD0103, 1000nM Tubastatin A) in H23 
(A) and A549 (B) cels. (C and D) Quantitation of selected MHC class I genes of IFNα/β 
pathway in response to Aza and/or HDACi in H23 (C) and A549 (D) cels (qRT-PCR, day 





















































































































































We also compared the eficacy of ITF-2357 against another hydroxamic acid derivative 
HDACi (SAHA). Using doses at equal ratio of cmax for the respective inhibitors, we 
observe a superior augmentation of interferon genes by ITF-2357 when deployed in 
combination with Aza (Figures 18A and 18B). The above studies demonstrate an 
induction of interferon-stimulated genes by Aza, which are further augmented by 




Figure 18: ITF-2357 is more potent than SAHA at facilitating ISG induction in 
combination with Aza 
 
(A and B) Expression of Interferon stimulated genes induced by Aza and/or the indicated 
HDACi in (A) A549 and (B) H23 cels (PCR genecard, day 8, 500nM Aza, 100nM ITF-








































Cancer/testis antigens are epigenetic treatment-responsive and have an established role 
in facilitating the recognition of tumors through immune surveilance (Moreno-Bost et al., 
2011; Oi et al., 2009; Weiser et al., 2001). We find in agreement with previous studies, 
the expression of cancer/testis antigens are Aza inducible, but a significant additional 









































































































































































































































































































































































































































Figure 19: Cancer/Testis antigens are Aza inducible with further augmentation 
noted through the application Aza + ITF-2357 
(A) Heatmap of relative RNA expression for cancer/testis antigen genes across NSCLC 
cel lines (microarray, day 8, 500nM Aza, 100nM MS275, 100nM ITF-2357). (B) 
Quantification of cancer/testis antigen transcriptional induction by combination Aza + 
HDACi treatment over Aza alone across NSCLC cel lines (microaray, day 8, 500nM 
Aza, 100nM MS275, 100nM ITF-2357; diferential gene expression cutof Log2 fold 
change over Aza >0.5). (C and D) Relative RNA expression of selected cancer/testis 
antigen transcripts in response to Aza and/or HDACi (qRT-PCR, day 8, 500nM Aza, 
100nM ITF-2357, 200nM MGCD0103, 2000nM RGFP996, 1000nM Tubastatin A, n=3, 












The augmentation of the IFNα/β pathway by Aza partialy relies on increasing dsRNA 
species, including ERV transcripts (Chiappineli et al., 2015; Roulois et al., 2015; Stengel 
et al., 2010; Strissel et al., 2012). Indeed, combination HDACi with Aza transcriptionaly 
induced multiple ERV’s across al cel lines tested (Figures 20A and 20B). We found 
ERV9-1 to be the most diferentialy expressed ERV induced by Aza + ITF-2357. Using 
isoform specific inhibitors in combination with Aza we determined its transcription is 
potentiated most robustly by inhibition of HDAC6(a cytoplasmic HDAC) (Figures 20C 
and 20D). The inducibility of interferon signaling from ERV transcription are linked in our 
NSCLC cels as single ERV overexpression induces transcription of OASL1, an 



























































































































































































































Figure 20: Combination epigenetic enhances the induction of ERVs over Aza 
alone 
(A and B) Quantitation of ERV transcripts in response to Aza and/or HDACi in H23 (A) 
and A549 (B) cels (qRT-PCR, day 8, 500nM Aza, 100nM ITF-2357, 100nM MS-275; n=4). 
(C and D) Quantitation of ERV9-1 in response to Aza and/or HDACi in H23 (C) and A549 
(D). (500nM Aza, 100nM ITF-2357, 200nM MGCD0103, 2000nM RGFP996, 1000nM 
Tubastatin A, n=3). (E) Efect of ERV overexpression on transcription of the interferon 
stimulated gene, OASL, in A549 and H23 cels (48-hour post transfection, qRT-PCR, 
ERV3 overexpressed in A549, SYN1 overexpressed in H23, n=4, data are mean ± SEM). 















In summary, Aza acts to sensitize NSCLC to the cytostatic actions of HDACi mainly 
through the inhibition of HDACs 1, 2, and 3. Combination epigenetic therapy deployed in 
vivo using our defined schema demonstrates eficacy in 3 independent immune 
incompetent mouse models, including a PDX model. HDACi’s enhance Aza induced 
interferon responsive gene transcription mediated most robustly through the inhibition of 
HDAC’s 1, 2, and 6. Class I antigen presentation is augmented through the inhibition of 
HDAC’s 1, 2, 3, and 6 in combination with Aza. While the induction of cancer/testis 
antigen transcription requires potent HDACi’s, such as ITF-2357, to mediate significant 
upregulation over Aza alone. 
 




Combination epigenetic therapy holds promise based on the predicted mechanism of 
gene re-expression as defined in depth previously. But true predictors of response and 
actionable targets of combination epigenetic therapy in NSCLC have not been defined. 
In this section, we aim to elucidate correlative biomarkers which are predictive of 
response to combination epigenetic treatment and to prove causation of this or these 
targets in eliciting the phenotypes observed. 
 




MYC targets heatmap: 
MYC targets heat maps are based on hierarchical clustering of Log2 fold change over 
mock using Euclidean distance and complete linkage of MYC halmarks gene set v2. 
 
MYC Immunobloting: 
Protein was extracted by 4% SDS mediated lysis, folowed by processing of lysates 
through homogenizer column (Omega). Protein concentrations were estimated by BCA 
(Pierce Biotechnology). Lysates were processed using PAGE with 4-12% Bis-Tris BOLT 
gel (Life Technologies) and transferred to PVDF membrane (Milipore). Membranes were 
blocked in 10% milk/TBST and immunobloted with the folowing antibodies.: rabbit 
monoclonal c-MYC (Cel Signaling, 1:1000, Mouse monoclonal anti-β-Actin (Sigma 
Aldrich, 1:10000). The loading control antibodies anti-β-Actin in al cases were applied 
after membrane stripping. 
 
MYC Knockdown Cel Viability Assay: 
MYC knockdown was initated using Broad TRCN0000010391 clone and control vector 
shGFP 5′- GCAAGCTGACCCTGAAGTTCAT3-3′. Clonal selection was initated with 
puromycin selection. Selected clones were plated at the cel densities and treated as 
described in Cel viabilty assay section of methods. MTS was used to quantify numbers 
of proliferating cels. Bar graphs depicted are representative of the percent of MYC 
knockdown cels present as a percentage of the empty vector treated controls for same 
dose of drug. Error bars are representative of mean +/- SEM between experimental 
replicates. Statistical significance was determined by two tailed t test between empty 
vector and MYC shRNA treated cels at each dose. 
 
MYC Overexpression Cel Viability Assay: 
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MYC vector (Addgene plasmid # 46970) (Cheng et al., 2013) and empty vector 
(Clontech cat# 632154). Clonal selection was initated with puromycin, 2 days post 
infection. Selected clones were plated at cel densities and treated as described in Cel 
viabilty assay section of methods. MTS was used to quantify numbers of proliferating 
cels. Bar graphs depicted are representative of the percent of MYC overexpression cels 
present as a percentage of the empty vector treated controls for same dose of drug. 
Error bars are representative of mean +/- SEM between experimental replicates. 
Statistical significance was determined by two tailed t test between empty vector and 
MYC overexpression vector treated cels at each dose. 
 
MYC overespression IFNα/β qPCR: 
qPCR methodology for detecting IFNα/β related genes (ISG15, OASL1, HLA-A, HLA-B) 
diferential expression was conducted on 20ng of cel line cDNA with SYBR green 
technology. Expression values were calculated as fold change over empty vector by 
delta-delta ct. Beta-actin was used as housekeeping gene for normalization of NSCLC 
cel line expression. 
 
MYC overexpression Taqman microfluidic genecard: 
1ug of total RNA was used for cDNA reaction and diluted to 50uL total volume in 
molecular grade water. Diluted cDNA was combined with 50uL of Taqman universal 
PCR mastermix and loaded onto a Taqman microfludic genecard with the folowing 
primer/probe sets preloaded: IRF7, IFI27, STAT1, IFNB1, MX1, OASL, IFI6, beta actin, 
TBP. Expression values were calculated as fold change over empty vector by delta-delta 
ct. Beta actin and TBP were used as housekeeping genes for normalization of NSCLC 






As described earlier DAVID analysis of the top 500 diferentialy expressed genes 
reveals three of the top eight pathways are MYC related (Figure 13C), suggesting the 
perturbation of MYC as a key target of our epigenetic therapy. Criticaly, in the tested 
NSCLC cel lines Aza produces a significant transcriptional downregulation of MYC, with 
an at least 1.4-fold reduction observed across al cel lines assayed (Figure 20A). These 
transcription data correlate with downregulation of MYC protein in A549 and H460 cels 
(Figure 20B). Additional assessment of MYC protein downregulation by Aza and priming 
to sequential HDACi across a panel of NSCLC cel lines of varying oncogenotypes 
revealed a significant corelation between degree of downregulation and HDACi 





















Figure 21: c-MYC depletion by Aza is correlated with eficacy of HDACi across 
oncogenotypes of NSCLC 
 
(A) Quantitation of relative MYC RNA expression in NSCLC cel lines folowing 500nM 
Aza treatment (microarray, day 8). (B) Immunoblot showing expression of MYC protein 
on day 9 of treatment. β Actin used as loading control (500nM Aza, n=3). (C) 
Immunoblot showing MYC expression in the indicated cel lines treated with Aza. β-Actin 
used as loading control. NR= non-responding cel line with no significant change in ITF-
2357 IC50 by Aza pretreatment dose response data, PR= partial responder, less than a 
25% reduction in ITF-2357 IC50 by 500nM Aza, R= responding cel line, greater than or 


















Aza + HDACi acts to further deplete MYC over Aza treatment alone (Figure 21A). The 
application of Aza and Aza + HDACi treatment induces potent repression of the top 200 








Figure 22: Combination epigenetic treatment further represses MYC signaling 
over Aza alone 
 
(A) Immunoblot showing MYC expression in H460 cels treated with Aza with or without 
HDACi. β-Actin used as loading control (Day 9, 500nM Aza, 100nM ITF-2357, 200nM 
MGCD0103, 2000nM RGFP996, 1000nM Tubastatin A, n=2) 
(B) Unsupervised hierarchical clustering of relative RNA expression for GSEA 
HALLMARK MYC TARGETS. Color gradation based on Z score ranking of log2 fold 




















Importantly, knockdown of MYC protein phenocopies the Aza sensitization of NSCLC to 
HDACi induced cytostasis (Figures 22A and 22C). The stable overexpression of MYC 
partialy rescues the Aza induced sensitization to HDACi induced cel depletion (Figures 
22B and 22D). These data indicate an Aza induced MYC depletion as a potent 
sensitizer to HDACi induced proliferative arrest, and accordingly implicate depletion of 


















































































































































































































































































Figure 23: c-MYC perturbation impacts the anti-proliferative efficacy of NSCLC 
response to HDACi 
 
(A) Immunoblot showing MYC expression in H460 and A549 cels infected with empty or 
MYC shRNA vector. β-Actin used as loading control. (day 4 of knockdown, n=2). (B) 
Immunobloting for MYC in H460 and A549 cels infected with empty vector or MYC over 
expression vector. β-Actin used as loading control (day 5 of overexpression, n=2). (C 
and D) A549 and H460 cel line quantitation of colorimetric absorbance as indicator of 
proliferating cel number, normalized to untreated control (C) Percent proliferation for 
GFP and shMYC vector infected cels treated with the indicated HDACi for 5 days (n=3). 
(D) Percent proliferation for empty vector (EV) or MYC overexpression vector containing 

















High MYC tumors have been reported to display resistance to IFNγ signaling and the 
action of cytotoxic T lymphocytes (Casey et al., 2016; Schlee et al., 2007a; Schlee et al., 
2007b). In this regard, exogenous MYC overexpression results in antagonism of 
interferon stimulated gene induction and antigen presentation induced by epigenetic 
treatment (Figures 23A and 23B). Thus, the MYC depletion signature imparted by Aza 






Figure 24: c-MYC overexpression antagonizes the induction of IFNαβ genes by 
epigenetic treatment 
 
(A and B) Relative RNA expression of IFNα/β pathway responsive genes in A549 cels 
infected with EV or MYC overexpression construct and treated with mock or 500nM Aza 
+ 100nM ITF-2357 (A) IFNα/β pathway - viral defense gene subset (genecard, day 8). 
(B) IFNα/β pathway- MHC class I genes (qRT-PCR, day 8, n=3). 
Data are presented as mean ± SEM. * p < 0.05 relative to mock, # p < 0.05 relative to 






















































































These data implicate MYC signaling and its downregulation as a key arbiter of the 
combination epigenetic treatment eficacy. Specificaly, the downregulation of MYC by 
Aza is significantly corelated with the eficacy of combination epigenetic therapy in 
terms of both cytostasis and IFN gene augmentation. Additionaly, perturbation of MYC 
levels through knockdown and overexpression studies alters the response to epigenetic 
therapy. This result is suggestive of direct MYC causation in the observed phenotypes. 
 
 
IV. Combination epigenetic treatment exerts a robust anti-tumor efect in 2 




The application of our combination epigenetic regimen to immune competent mouse 
models alowed us to simultaneously validate both our immune dependent and immune 
autonomous phenotypes derived from our in vitro schemas. To accomplish these ends 
we deployed our regimen in both an interception early intervention genetic mouse model 
LSL-KrasG12D and an aggressive adenocarcinoma mouse model Lewis Lung 
Carcinomas. Both phenotypic and transcriptomic parameters were assayed to evaluate 
therapeutic eficacy of combination epigenetic treatment. 
 
2. Materials and methods 
 
LSL-KrasG12D mouse model: 
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LSL-KrasG12D mice (Jackson et al., 2001) were obtained from Jackson laboratories and 
bred with wild type C57BL/6 mice to generate heterozygous LSL-KrasG12D mice. LSL-
KrasG12D mice (8-10 weeks, both genders) were infected intratrachealy with Adenoviral 
vectors encoding Cre (obtained from University of Iowa) to activate Kras. LSL-KrasG12D 
mice harbor a latent point-mutant alele of Kras (KrasG12D) and infection with an 
adenoviral vector encoding Cre leads to Cre-mediated deletion of a transcriptional 
termination sequence (Lox-Stop-Lox, LSL) and the oncogenic Kras production, thereby 
resulting in very high frequency of lung tumors (Jackson et al., 2001). Al experimental 
animal protocols were performed in accordance with guidelines approved by the animal 
care and use commitee at the Johns Hopkins University (Baltimore, MD). Mice were 
examined for presence of disease at 16 weeks post infection with AdenoCre. Mice were 
sacrificed and lungs were examined histologicaly. At this stage most of the mice showed 
presence of significant regions of hyperplasia as wel as adenomas. Drug treatments 
were started as per the schedule shown in Figure S7A. Mice were divided in two groups. 
Once group was injected with vehicle control while the other was injected with 
combination epigenetic drugs. Mice were uniformly distributed into the two treatment 
groups so that each group had comparable numbers of age and weight matched male 
and female mice. 
 
Lewis lung Carcinoma (LLC) model : 
 LLC cels (LLC1, ATCC) 2.0 x 104 were injected subcutaneously in flanks of male C57BL6 
mice (6-8 weeks old) obtained from Harlan. LLC1 cels were suspended in 100uL RPMI + 
Matrigel (1:1). Drug treatments were started 7 days post injection when palpable tumors 
could be discerned. Mice were injected with drugs as per the dosing schema in Figure 
S7A. Treatment was continued for a month folowed and at the culmination of study mice 
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were sacrificed, tumors were harvested and weighed. Lungs of these mice were inflated 
and fixed in formaldehyde for 24 hours prior to sectioning and staining with H&E stains. 
In-vivo Drug Studies: 
Mice were treated as folows: Azacitdine 0.5 mg/kg (PBS vehicle) IP injected daily for the 
first 5 days of every 14 day treatment cycle. In vivo HDACi was applied on day 7 of 14 
day treatment cycle and injected daily for 5 days of 14 day cycle. ITF-2357 2.0 mg/kg 
(1% DMSO in PBS vehicle) IP injected daily for 5 days sequentialy, every 14 days. MS-
275 2.0 mg/kg (1% DMSO in PBS vehicle) IP injected daily for 5 days sequentialy, every 
14 days. MGCD0103 4.0 mg/kg (5% DMSO in PBS vehicle) IP injected daily for 5 days 
sequentialy, every 14 days. InVivoMAb mouse Anti-PD1 (BioXcel RMPI 14 clone) 
injected 10ug/kg on the 12th day of a 14 day cycle. InVivoMAb Rat IgG2a Isotype control 
(BioXcel 2A3 clone) injected 10ug/kg on the 12th day of a 14 day cycle. CD8a depletion 
antibody (BioXcel, 2.43 clone), 3 times per week at 150ug per animal, see LLC CD8 
depletion model for details about the treatment schema. For xenograft studies, treatment 
was iniated 10 days post injection when palpable tumors could be discerned and 
continued for 37 days. For Kras G12D mouse model studies, drug application initated 16 
weeks post Ad-Cre instilation, and applied for 12 weeks as described in the Kras G12D 
animal model section. For LLC model treatment was initated 7 days after subcutaneous 
implant of flank tumor and mice were treated as described in (Figure S7A). Mice were 
injected IP with 150ug of CD8a antibody (BioXcel), three times per week throughout the 
duration of study. CD8 depletion was verfied by assesment of CD8% of CD45 population 
in the spleen of depleted sample vs. control samples.    
 
Histological analysis of mouse tissues: 
Lungs tissues were fixed in 10% formalin overnight, and subsequently transfered into 
70% ethanol, embedded in parafin and sectioned (5 µM) at 3 levels at regular intervals. 
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Sections were stained with Hematoxylin and eosin (H&E) and scanned using the Aperio 
whole slide scanning system (Scanscope CS) The entire left lung lobe was scanned for 
presence of adenomas/adenocarcinomas using the Aperio ImageScope analysis 
software. For each sample, sections from 2 levels were analyzed. Unstained sections of 
the left lung were also used for Immunohistochemistry (IHC) staining. Al Images were 
scanned at 20x magnification using the Aperio Scanscope system. 
 
Immunohistochemistry (IHC): 
Immunostaining of lung sections was performed with the PowerVision kit according to 
the manufacturer’s protocol (Leica Biosystems). Briefly, slides were heated at 60°C for 
10 min,deparafinized and hydrated through xylene, graded ethyl alcohols, dH2O, dH2O 
with 20% Tween 20 (P-7949, Sigma-Aldrich). After antigen retrieval (45 minutes of 
steaming in Target Retrieval Solution (Dako S170084-2) using Black and Decker Handy 
Steamer Plus), sections were treated 5 minutes with Dual Endogenous Enzyme Block 
(S2003, Dako). Sections with primary antibodies Ki67 (Cel signaling, 9101, 1:500) 
were incubated at room temperature for 45 minutes. Secondary used was anti-rabbit 
IgG-reagent provided in the Powervision kit (PV6119, Leica Biosystems) for 30 minutes.  
Immunostaining was visualized with DAB chromogen (D4293, Sigma-Aldrich) and 
sections were counterstained with Mayer's hematoxylin. Control slide: No primary 
control. 
 
Gene expression analysis by microaray: 
RNA expression were conducted by microaray for the conditions descibed in the 
relevant figures. The R/Bioconductor package limma was used to process expression 
data. Within- and between-array normalizations were performed using the loess and 
aquantile methods, respectively. The normexp option was used for background 
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correction. Raw files read in using the read.maimages function. Log2 fold change in 
transcription for drug treated conditions over mock treated was obtained for each sample 
at each time point studied. Ranked lists of log2 fold change were analyzed using Gene 
Set Enrichment Analysis (GSEA) by the Broad Institute and data packages 
(Subramanian et al., 2005). Pathways enriched with a false discovery rate less than 0.25 
were selected with cutof 1.5 normalized enrichment score cutof in mouse studies. 
Median absolute deviation analysis of Log2 fold change transcription data were obtained 
using Morpheus program (Broad). 
 
3. Results 
The translational potential for utilizing our chronic schema of alternating, low dose 1-
week Aza folowed by 1-week ITF-2357 is apparent from robust eficacy when tested in 
two mouse models of NSCLC. The first, the LSL-KrasG12D mouse model of NSCLC, 
represents an interception model as we began treatment when lung adenomas emerge 
16 weeks folowing the lung specific activation of the mutation (Jackson et al., 2001). 
Mice were treated with the combination drug treatment for 3 months using the schema 
as shown in Figure 24A. The therapy is wel tolerated and while mock treated mice 
developed large adenocarcinoma lesions in the lungs, combination epigenetic treatment 
prevents the occurrence of these macroscopic lesions and caused over a 60% reduction 
of tumor area in the treated mice (Figures 24B and 24C). Consistent with al the studies 
in the human NSCLC cels, proliferation as assessed by ki67 positivity is markedly 
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Figure 25: Combination epigenetic therapy reduces burden, progression and 
proliferation of LSL-KrasG12D model 
 
(A) In vivo treatment schema for Aza + ITF2357 applied to a LSL-KrasG12D murine model 
of NSCLC (B) Macroscopic images of LSL-KrasG12D lungs treated with vehicle or Aza 
and ITF-2357, for 3 months (n=7 mock and n=8 Aza + ITF-2357). (C) Representative H 
& E stained images of murine lung sections treated with mock or Aza + ITF-2357 (n=6 
mock, n=7 Aza + ITF-2357 per group). Scale bar = 100 µ. Quantitation of total tumor 
area occupied by lesions in lungs of LSL-KrasG12D mice treated with mock or Aza + ITF-
2357. Data are presented as mean ± SEM, p value determined by two tail t test (n=6 
mock, n=7 Aza + ITF-2357 mice per group/2sections analyzed per mouse). (D) 
Representative Ki67 stained IHC images of murine lung sections treated with mock or 
















The translational potential for our combination epigenetic drug eficacy for established, 
aggressive NSCLC is apparent utilizing a second mouse model of NSCLC, Lewis Lung 
Carcinoma (LLC). This murine model has demonstrated high corelation between 
response in the animal and response in the clinic for 2 therapeutic regimens (Kelar et 
al., 2015). Treatment with our alternating schedule of Aza + ITF-2357, and of Aza + 
MGCD0103 for 1 month, not only reduces growth of established and rapidly growing 
primary tumor explants of the LLC cels, but dramaticaly reduces metastatic occurence 














Figure 26: Combination epigenetic treatment of LLC model reduces both primary 
and metastatic burden 
 (A) Lewis lung carcinoma (LLC) tumor weights of subcutaneous explants from one-
month mock and Aza + ITF-2357 treated mice (n=19 mice per group, eror bars SEM). 
Representative H & E stained images of lung metastasis from LLC mice obtained from 
one-month mock and Aza + ITF-2357 treated mice (n=12 mice per group) with indicated 
percentage frequency of metastasis. (B) Lewis lung carcinoma (LLC) tumor weights for 
subcutaneous explants from one-month mock and Aza + MCCD0103 treated mice (n=19 
mock, same mice represented in Figure 5D, and n=12 Aza + MGCD0103). 
Representative H & E stained images of lung metastasis from these mice. Percentage 
frequency of this is event shown on the right. 
The image part with relationship ID rId54 was not found in the file.
The image part with relationship ID rId54 was not found in the file.
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Transcriptomic analysis of combination epigenetic treatment in murine NSCLC model 
Importantly, as outlined below, the above eficacy of our combination therapy is 
accompanied by profound immune efects. First, in the LSL-KrasG12D mice, the 
combination epigenetic treatment profoundly altered the tumor transcriptome with 5167 
significantly upregulated and 4540 downregulated genes (Figure 26A). This 
corresponds to 18 gene sets upregulated and 52 gene sets downregulated by GSEA 
analyses with the former predominantly associated with immune parameters and the 
later with cel cycle pathways, respectively (Figure 26B). Similar to the results for 
human NSCLC lines, 12 of the 18 gene sets upregulated involved strong induction of 
cytokine and interferon related gene sets (Figure 26C) as wel as for 24 genes involved 
with inflammatory responses (Figure 26D). Concomitantly, as for the human NSCLC 
lines, most of the down-regulated cel cycle pathways involved myc pathway signaling 



















Figure 27: Combination epigenetic treatment induces tumor immune signature 
with a correlated repression of proliferation and MYC related signaling 
(A) Volcano plot of relative RNA expression from LSL-KrasG12D mice tumors treated for 3 
months with Aza + ITF-2357 as compared to mock mice. Genes in upper left and right 
quadrants are significantly, diferentialy expressed (microaray, n=2 per group). (B) 
GSEA (KEGG, REACTOME, HALLMARK gene ontologies) pathway distribution for Aza 
+ ITF-2357 vs. mock tumors from LSL-KrasG12D mice. Horizontal line denotes FDR 
significance cutof of 0.25. Immune and cel cycle related gene sets are demarcated by 
green and red dots respectively (microarray, n=2 per group). (C) Gene sets upregulated 
in LSL-KrasG12D mice (< FDR 0.25 and > NES 1.5) by Aza + ITF-2357. Color gradation 
The image part with relationship ID rId54 was not found in the file.
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based on GSEA NES. (D) Representative upregulated GSEA plots with coresponding 
core enriched genes; color gradation representative of Log2 fold change over mock. (E) 
Gene sets downregulated in LSL-KrasG12D mice (< FDR 0.25 and < NES 1.5) by Aza + 
ITF-2357. Color gradation based on GSEA NES. (F) Representative Downregulated 
GSEA plot with core enriched genes; color gradation representative of Log2 fold change 
over mock treated RNA expression. 
 
4. Discussion 
These data demonstrate a potent reduction in tumor proliferation, growth, and burden is 
induced by combination epigenetic treatment in 2 independent mouse models of 
NSCLC. Additionaly, we observe a transcriptional signature similar to the noted 
response in the human NSCLC cel lines. These data demonstrate that immune related 
signaling and MYC pathway downregulation is a conserved response to combination 
epigenetic therapy and suggest these pathways may be tied to therapeutic eficacy both 
in vitro and in vivo. 
 
V. Combination epigenetic treatment alters the tumor immune microenvironment, 




The immune related signaling noted in the whole tumor transcriptomics provided the 
suggestion that the immune microenvironment could be altered by the application of 
combination epigenetic treatment in vivo. In an efort to understand the immune 
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microenvironment, we sought to define the polarization of both infiltrating macrophages 
and lymphocytes into the tumor microenvironment. These data aided in delineating the 
respective roles of these populations in both the phenotype observed and the whole 
tumor transcriptional signature noted. 
 
2. Materials and methods 
 
Immunohistochemistry (IHC): 
Immunostaining of lung sections was performed with the PowerVision kit according to 
the manufacturer’s protocol (Leica Biosystems). Briefly, slides were heated at 60°C for 
10 min,deparafinized and hydrated through xylene, graded ethyl alcohols, dH2O, dH2O 
with 20% Tween 20 (P-7949, Sigma-Aldrich). After antigen retrieval (45 minutes of 
steaming in Target Retrieval Solution (Dako S170084-2) using Black and Decker Handy 
Steamer Plus), sections were treated 5 minutes with Dual Endogenous Enzyme Block 
(S2003, Dako). Additional blocking steps were used for CD8 and F4/80 slides using 
DakoCytomation Biotin Blocking System (X0590). Antibody incubations for CD8 
(eBiosciences, 14-0808, 1:800) and F4/80 (Serotec, MCAP497, 1:1000) were carried out 
at room temperature for 45 minutes, soaked an additional 45 min in PBS-Tween, and 
folowed by mouse adsorbed biotinylated anti Rat IgG (Vector, BA-4001, 1:500) for 15 
minutes. For al, the secondary used was anti-rabbit IgG-reagent provided in the 
Powervision kit (PV6119, Leica Biosystems) for 30 minutes.  Immunostaining was 
visualized with DAB chromogen (D4293, Sigma-Aldrich) and sections were 
counterstained with Mayer's hematoxylin. Control slides: No primary for each, CD8 
(spleen), F480 (tumor) 
 
F4/80 Intratumor Macrophage Analysis: 
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F4/80 IHC stained sections were scanned used the Aperio system as described earlier, 
these images were analyzed use imagescope software. To generate the false color 
images depicted, used to demarcate pixel saturation by macrophage infiltration, the 
images were analyzed by the positive pixel v4 algorythm. 
 
Isoation of murine bone marow derive macrophages (BMDMs): 
Mice (6-8) week old were euthanized and hind legs were harvested under aseptic 
conditions. Femors and tibia were obtained and flushed with RPMI medium. Cels were 
then centrigued and treated with ACK bufer to lyse RBC’s. Cel pelets with then washed 
with and resuspended in RPMI medium and plated in six wel plates in the presence of M-
CSF. Medium was changed every 2 days. Treatments with Aza and HDACi were started 
after 4 days and the in vitro drug treatment schema was 5 days of Aza folowed by either 
vehicle or the indicated HDACi (see figure) for 5 days. Cels were then colected and RNA 
extracted. 
 
FACS sorting and profiling of macrophages and T cels LSL-KrasG12D: 
For FACS sorting of macrophages and CD8 T cels from LSL-KRasG12D mice, lungs were 
harvested from mock or treated mice folowing three months of treatment. Tissue was then 
digested for 30 minutes at 37 deg C in digestion bufer (RPMI, FBS (10%), Colagenase 
Type 1 (0.2%), Colagenase Type 2 (0.2%) and DNase I (50u/mL). Tissue was then 
minced and strained through a 40um cel strainer to obtain a single cel suspension. RBC’s 
were then lysed with ACK bufer and the cel pelet was washed twice in RPMI prior to 
suspension in RPMI medium. Cels were then counted and blocked with Rat monoclonal 
anti-CD16/CD32 (Fc block Antibody) in PBS for 30 min at 4 deg C. Cels were then stained 
with antibodies against CD45, Cd11b and F4/80 for macrophages or CD45, CD3, CD8a 
for CD8+ T-cels. Propidium Iodide was used as a viability marker (5uL/100uL total 
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volume). Cels were sorted and pelets were lysed and RNA extracted using RNeasy kit. 
RNA was then quantitated and amplified using the Sigma Whole Transcriptome 
Amplification kit. Amplified RNA was then processed and analyzed on an Agilent 4x44 
single color microarray. Post sort purity checks were utilized and the sorted populations 
were determined to be more than 95% pure population. 
 
FACS profiling T cels LSL-KrasG12D: 
For FACS sorting of macrophages and CD8+ T cels from LLC mice, primary tumors were 
harvested from mock or treated mice folowing one month of treatment. Tissue was then 
digested using a mixture of colagenase, hyaluronidase and DNase. The resulting single 
cel suspension was counted and plated at in complete media (RPMI+10% FBS) with or 
with eBiosciences stimulation cocktail (1:1000) for 4 hours. Cels were then colected and 
blocked with Rat monoclonal anti-CD16/CD32 (Fc block Antibody) in PBS for 30 min at 4 
deg C. Cels were then stained with antibodies against Live/dead, CD45, CD3, CD8a, and 
IFNγ for CD8+ T-cels. Cels were then profiled by FACS. 
Immune cel infiltration data: 
 IHC quantification- tumor infiltrating CD8 T cels were enumerated in field of view for 
hotspots of infiltration for the conditions indicated in the figure. The n values depicted 
indicate individual animals scored for infiltration. p values for IHC quantification data were 
derived using Graphpad Prism software and were defined as <0.05 by unpaired two tailed 
t test when comparing treated condition versus control, independent animals were used 
for the derivation of significance. FACS infiltration data- tumor infiltrating CD8 T cels were 
profiled from whole digested tumors. The n values depicted indicate individual animals 
profiled by FACS. p values for FACS data were derived using Graphpad Prism software 
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and were defined as <0.05 by unpaired two tailed t test when comparing treated condition 
versus control, independent animals were used for the derivation of significance. 
 
Gene expression analysis by microaray: 
RNA expression were conducted by microarray for the conditions descibed in the relevant 
figures. The R/Bioconductor package limma was used to process expression data. Within- 
and between-array normalizations were performed using the loess and aquantile methods, 
respectively. The normexp option was used for background corection. Raw files read in 
using the read.maimages function. Log2 fold change in transcription for drug treated 
conditions over mock treated was obtained for each sample at each time point studied. 
Ranked lists of log2 fold change were analyzed using Gene Set Enrichment Analysis 
(GSEA) by the Broad Institute and data packages (Subramanian et al., 2005). 
Hypergeometric test of cumulative distribution function: 
 The number of overlapping genes present in the Wherry et al. 2007 and our RNA 
expression data set (>0.5 log2 fold change, p value <0.05) were used to calculate over 
representation of these genes. p values were calculated using hypergeometric test of 





In the above mouse models, deployment of epigenetic treatment reverses tumor immune 
evasion status and a significant perturbation of tumor associated immune cel subsets 
appears to underlie the eficacy of the drug combinations. First, there is a robust 
alteration in the distribution of F4/80+ macrophages which have been shown to have an 
established role in the progression of the LSL-KrasG12D mouse model (Okayama et al., 
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2013) These cels have been shown to basaly infiltrate tumors induced in this model and 
our combination treatment results in a significant decrease in their numbers (Figure 
27A). Transcriptional profiling of tumor associated macrophages (TAMs) isolated by 
FACS sorting of F4/80hi, CD11b+ macrophages from the lungs folowing the three 
months of combination epigenetic treatment revealed diferential expression of 1104 
genes (Figure 27B) including significant downregulation of angiogenesis and hypoxia 
responsive genes and gene sets (Figure 27C). These observed perturbations appear to 
be a direct efect of the treatment and not a function of tumor stage, as treatment of 
normal bone marow derived macrophages (BMDM) in vitro induces angiogenic 
signature downregulation as part of the 2295 diferentialy expressed genes (Figures 





















Figure 28: Combination epigenetic therapy reduces both macrophage infiltration 
and angiogenic signatures 
(A) Representative IHC staining of F4/80+ macrophages with F4/80 in LSL-KrasG12D lung 
tumor sections treated with mock or Aza + ITF-2357 for 3 months. Upper panel: 
Representative F4/80+ IHC; Lower panel: Positive pixel transformation of IHC images in 
upper panel using Aperio Imagescope software. Scale bar = 100 µ (B) Volcano plot of 
relative RNA expression from FACS sorted CD45+CD11b+F4/80hi macrophages isolated 
from tumor bearing lungs from 3-month mock or Aza + ITF-2357 treated LSL-KrasG12D 
mice. Genes in upper left and right quadrants are significantly, diferentialy expressed 
(microarray, n=2 per group). Hypoxia and angiogenic pathway associated genes are 
highlighted. (C) Key afected pathways obtained from GSEA of CD45+CD11b+F4/80hi 
macrophage RNA isolated from tumor bearing lungs from 3-month Aza + ITF-2357 
treated LSL-KrasG12D mice as compared to mock treated mice. (D) Log2 fold relative 
RNA probe distribution showing diferential gene expression from bone marrow derived 
The image part with relationship ID rId54 was not found in the file.





macrophages (BMDMs) treated in vitro with mock or Aza + ITF-2357. Angiogenic 
pathway associated genes are highlighted. (microarray, BMDM data representative of 




















The above altered pathways in TAMS may have implications for mediating CD8+ T cel 
intra-tumor infiltration. The inhibition of angiogenesis has proved eficacious in the 
MMTV mouse model through facilitating an increase in CD8+ tumor infiltrating 
lymphocytes (Huang et al., 2012). This anti-angiogenic based strategy for the induced 
infiltration of T lymphocytes depends on the concept of vascular normalization (Huang et 
al., 2013). Therefore, the repression of angiogenic programs in macrophages may act 
localy in the tumor to create a more immune infiltrate permissive environment in the 
LSL-KrasG12D. 
Criticaly, there is increased CD8+ tumor infiltrating lymphocytes (TILs) in the tumor 
microenvironment of treated mice (Figure 28A). This enhanced TIL accumulation is 
accompanied by an IFNγ responsive signature in the transcriptional profile of LSL-
KrasG12D whole tumor lysates (Figure 28B). As a validation of this 
signature, we profiled TILs by FACS in the LLC model and although we did not see any 
change in total CD8 numbers in this short-term treatment model, we observed a 2.25-
















Figure 29: Combination epigenetic therapy induces the accumulation of activated 
T cels in the tumor microenvironment 
(A) CD8+ IHC in lung tumors of mock and Aza + ITF-2357 treated LSL-KrasG12D mice 
folowing 3 months of treatment, scale bar = 100 µ. The graph on the right indicates the 
average number of CD8+ T cels counted per field of view (FOV) intra-tumor for mock 
and treated mice. (n=6 mock, n=7 Aza + ITF=2357 mice). (B) Relative RNA expression 
based enrichment plot for ‘halmark interferon gamma response’ gene set in tumors from 
LSL-KrasG12D mice treated with mock and Aza + ITF-2357. Color gradation is 
representative of Log2 fold change over mock RNA expression (microaray, n=2 per 
group). (C) Percentage Ifnγ+ CD8+/CD3+ TILs by FACS in LLC subcutaneous tumors 
from one-month mock and Aza + ITF-2357 treated mice. 
The image part with relationship ID rId54 was not found in the file.





Transcriptional profiling of TILs from control and treated tumors in the LSL-KrasG12D mice 
suggests a key role of epigenetic therapy on these cels. TILs are known to acquire an 
exhaustion state in response to continuous stimuli and interaction with inhibitory ligands 
(Whery and Kurachi, 2015; Zehn and Whery, 2015). Therefore, the reversion or 
prevention of this exhausted state remains a major hurdle for durable T cel mediated 
anti-tumor responses. A recent study by Ghoneim et al. established the utility of 
demethylating agents to reverse CD8+ T cel exhaustion, thereby alowing this population 
to be actionable by PD-1 blockade (Ghoneim et al., 2017). Our epigenetic treatment 
regimen induces alteration of the TIL transcriptome. Comparative analysis of our 3698 
diferentialy expressed TIL genes (Figure 29A) revealed downregulation of exhaustion 
associated genes, and induction of activation and memory associated genes as defined 
by Wherry et al (Wherry et al., 2007). Our gene signature reflects an admixture of 























Figure 30: Combination epigenetic therapy skews TIL phenotype towards memory 
and efector fates 
(A) Volcano plot of relative RNA expression for CD45+CD3+CD8+ FACS obtained 
lymphocytes isolated from tumor bearing lungs of 3-month Aza + ITF-2357 treated LSL-
KrasG12D mice as compared to mock mice. Genes in upper left and right quadrants are 
significantly, diferentialy expressed (microarray, n=2 per group). Highlighted genes are 
involved in T cel fate determination. (B and C) Fold change in expression of selected 
diferentialy expressed genes in FACS obtained T cels from 3-month Aza + ITF-2357 
treated mice. Genes shown are those which overlapped with exhaustion versus memory 
signatures (B) or exhaustion versus efector signatures (C) queried from Wherry et al. as 
defined in results. Genes on the left of each panel were diferentialy expressed by Aza + 
ITF-2357 and directionality in the gene set queried is on the right, red=upregulated and 
blue=downregulated. The associated p value for the probability of overlap as derived by 
















The application of epigenetic treatment reduces the infiltration of macrophages into the 
tumor microenvironment. Additionaly, we note a repression of angiogenic signatures 
associated with this population. We also observe a significant alteration of T cel 
phenotypes in the tumor microenvironment with a skewing away from exhausted 
towards memory and efector T cel phenotypes. 
 The expansion of these efector/memory T cel populations is associated with durable 
responses to immune checkpoint blockade (Ribas et al., 2016). Thus, through the 
deployment of epigenetic treatment in two animal models, we confirm epigenetic 
treatment can both increase activated CD8s in an inflamed tumor and induce the 
atraction of efector-memory CD8s to an immune desert tumor. 
 
VI. Combination epigenetic treatment inhibits tumor growth through CD8+ T cels 




The above demonstrated therapy efects can potentialy reduce a barier to immune 
therapy, namely, the failure of tumors to atract functional CD8+ T cels. This leads to the 
question of whether the eficacy of epigenetic therapy is dependent on T cels in the 
tumor microenvironment and what events imparted by the therapy which may act to 
induce the noted T cel atraction. 
 




LLC model CD8 depletion model: 
CD8a antibody (BioXcel, 2.43 clone) meidated CD8 depletion of male C57BL6 mice was 
intiated 3 days prior to onset of treatment (Day 4 post implantation). Implantation and 
therapeutic treatment of CD depleted LLC model is described in Lewis Lung Carcinoma 
model section of methods. For CD8 depletion mice were injected IP with 150ug of CD8a 
antibody (BioXcel, 2.43 clone), three times per week throughout the duration of study. 
CD8 depletion was verfied by assesment of CD8% of CD45 population in the spleen of 
depleted sample vs. control samples. Treatment was continued for a month folowed and 
at the culmination of study mice were sacrificed, tumors were harvested and weighed. 
Lungs of these mice were inflated and fixed in formaldehyde for 24 hours prior to 
sectioning and staining with H&E stains. 
 
Gene expression analysis by microaray: 
RNA expression were conducted by microarray for the conditions descibed in the relevant 
figures. The R/Bioconductor package limma was used to process expression data. Within- 
and between-array normalizations were performed using the loess and aquantile methods, 
respectively. The normexp option was used for background corection. Raw files read in 
using the read.maimages function. Log2 fold change in transcription for drug treated 
conditions over mock treated was obtained for each sample at each time point studied. 
Ranked lists of log2 fold change were analyzed using Gene Set Enrichment Analysis 
(GSEA) by the Broad Institute and data packages (Subramanian et al., 2005). Pathways 
enriched with a false discovery rate less than 0.25 were selected with cutof of 2.0 
normalized enrichment score in human and 1.5 normalized enrichment score cutof in 
mouse studies. 
 
Bronchoalveolar lavage (BAL) fluid cytokine analysis: 
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1.0 mL of BAL fluid was instiled into the right lung of tumor bearing KrasG12D mice. 50uL 
of this BAL was utilized for cytokine analysis as described by the manufacturer 
(Raybiotech, QAM-CYT-1). Cytokine array was scanned by the manufacurer. Cytokine 
quantifcation was conducted using a standard curve of each cytokine present at known 
concentrations supplied by the manufactuer. p values for cytokine data were derived using 
Graphpad Prism software and were defined as <0.05 by unpaired two tailed t test when 
comparing treated condition versus control, biological replicates were used for the 
derivation of significance. Data are mean +/- SD between biological replicates. 
 
TCGA Analysis : 
Broad Morpheus tool was used to analyze TCGA LUAD data for the relationship 
between CCL5 and MYC. First the 2 genes were selected from available RNA seq data 
of 576 patients available. These data were used to generate a new heat map. This new 
heat map was sorted based on CCL5 and MYC expression and the samples were 
separated into low, intermediate and high expression groups. These subsets were than 
compared using the profile interaction tool, to generate the depicted plots. 576 LUAD 
samples were ranked by expression of CCL5 and MYC into: low, intermediate and high 
expression groups. These 3 expression categories for MYC and CCL5 were then 
compared as folows on the Y-axis, where gene(y) is sorted based on low, intermediate 
or high expression of other gene: MYC high:CCL5(y), MYCintermediate:CCL5(y), 
MYClow:CCL5(y), MYC(y):CCL5high, MYC(y):CCL5intermediate, MYC(y):CCL5low. 
 
Patient and sample characteristics used for MYC amplification studies: 
We analyzed pre-treatment exome data derived from a recently published set of NSCLC 
patients treated with immune checkpoint blockade (Anagnostou et al., 2017). Patient and 
sample characteristics as wel as treatment and response assessments are described in 
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detail elsewhere (Anagnostou et al., 2017). In brief, our study group consisted of two 
NSCLC patients treated with PD-1 blockade (CGLU117T1 and CGLU127T1) and two 
NSCLC patients treated with combined PD-1 and CTLA4 blockade (CGLU116T1 and 
CGLU161T1). Al patients achieved a partial response of more than six months in 
duration (durable clinical benefit-DCB) apart from CGLU117T1, who achieved stable 
disease (22% tumor regression by RECIST 1.1) of 4 months duration before he 
developed disease progression (non-durable clinical benefit-NCB). An additional NSCLC 
tumor sample from a patient with sustained response to PD-1 blockade was obtained for 
comparative analysis of CD8+ T-cel density.  
 
Somatic Copy Number Analysis: 
Whole exome sequence data from a previously published cohort of four patients with 
NSCLC (Anagnostou et al., 2017) was evaluated to determine the somatic copy number 
of MYC locus in pre-treatment tumor samples. The sequencing depth of coverage of the 
tumor sample in bins spanning coding and non-coding regions of the genome were 
compared to the matched normal sample from each patient. The log2 read ratio values 
were corrected for biases resulting from the exome capture process and sequence 
composition using CNVKit (0.7.6) (Talevich et al., 2016), and were adjusted to account 




Depleting CD8+ T cels in the LLC mouse model atenuated the eficacy of epigenetic 
treatment on the reduction of primary tumor burden (Figure 30). Relative to the Aza + 
ITF-2357 eficacy established in Figure 25, we also observe an increase in both 
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metastatic frequency and burden as the result of CD8 depletion. In the CD8 depleted 
environment we noted a metastatic frequency of 33% in mock and 20% in Aza + ITF-
2357 treated mice (Figure 30). 
 
 
Figure 31: CD8 depletion in LLC model strongly antagonizes the eficacy of 
combination epigenetic therapy. 
Weights of subcutaneous LLC tumors from one-month mock and Aza + ITF-2357 mice 
treated in the presence of CD8a depleting antibody (n=7 mock and n=5 treated mice) 
and representative H & E stained images of lung metastases from above one-month 
mock and Aza + ITF-2357 mice treated in the presence of CD8a depleting antibody (n=7 






The image part with relationship ID rId54 was not found in the file.
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Additionaly, in response to our combined epigenetic treatment there is transcriptional 
augmentation of CCL5, a secreted chemokine involved in lymphocyte atraction (Figure 
31A). Importantly, protein levels of CCL5 also accumulate in bronchoalveolar lavage of 
mice treated with combination epigenetic therapy (Figure 31B). This protein and its 
ligand have been identified as the primary factors influencing T cel infiltration of 
melanoma post-chemotherapy (Hong et al., 2011). This suggests that the enhanced 
levels of CCL5 induced by the epigenetic treatment may contribute to the increased 
























Figure 32: T cel atraction is correlated with an induction of the T cel atractant 
cytokine CCL5 
 
(A) Expression of ccl5 RNA in lung tumors from LSL-KrasG12D mice in response to 3 
months treatment with mock or Aza + ITF-2357 (microaray, n=2, p value < 0.05). (B) 
Quantitation of ccl5 protein levels in bronchoalveolar lavage from LSL-KrasG12D mice 











Several key findings suggest the importance of the above CCL5 results and link this 
parameter with the combination treatment mediated downregulation of MYC signaling. 
First, expression of exogenous MYC in human A549 NSCLC cels acts as a potent 
repressor of CCL5 transcriptional induction in response to epigenetic treatment (Figure 
32A). This links perturbation of MYC by epigenetic treatment to the alteration of immune 
correlates. Second, the potentialy repressive role of MYC on CCL5 is also apparent in 
Cancer Genome Atlas project (TCGA) primary NSCLC, lung adenocarcinoma (LUAD) 
samples, wherein there is an inverse relationship between CCL5 and MYC RNA 
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Figure 33: CCL5 and MYC expression are inversely correlated in TCGA 
adenocarcinoma patient samples 
(A) Relative fold change for CCL5 RNA expression in empty vector (EV) or MYC 
overexpressing A549 human NSCLC cels treated with 500nM Aza and/or 100nM ITF-
2357 (qRT-PCR, Day 8, n=3, Data are presented as mean ± SEM, * p value < 0.05 
relative to EV, # p value < 0.05 relative to EV + Aza + ITF-2357). (B) Profile interaction 
















Finaly, our new findings in a smal, previously reported cohort of patients with NSCLC 
treated with immune checkpoint therapy (Anagnostou et al., 2017) provide a suggestion 
for the importance of the present pre-clinical findings for the role of MYC signaling in 
response to immune therapy. In these four patients, al but one achieved durable clinical 
benefit with partial responses for greater than 6-months as defined by RECIST 1.1. 
Genome-wide copy number variation analysis on the tumors of these patients revealed a 
significant amplification of the MYC locus only in the one patient who did not achieve 
durable benefit (Figure 33). Of note, the tumors from al four patients had characteristics 
predicting favorable response to checkpoint blockade therapy (Anagnostou et al., 2017) 
including high PD-L1 protein expression and high mutation density (Rizvi et al., 2015; 







The image part with relationship ID rId54 was not found in the file.





Figure 34: MYC amplification antagonizes response to immune checkpoint 
blockade in smal cohort of NSCLC patients 
. (A) Somatic copy number status of the MYC locus in NSCLC tumors. A 1.13 Mbp 
segment overlapping MYC harbored a 12-fold amplification in CGLU117T1, the tumor 
that did not derive durable clinical benefit from immune checkpoint blockade. Orange 
lines represent segments of constant copy number. Circle and triangle markers indicate 
genomic bins in coding (target) and non-coding (of-target) regions, respectively. (B) 
Copy number status of chromosome 8. The heatmap depicts segmental copy ratios after 
tumor purity corection, highlighting the amplification of the MYC locus for CGLU117T1 
















These data demonstrate a corelative link between T cel atraction and induction of the 
potent T cel atractant CCL5. Furthermore, we demonstrate the causation of T cels in 
an aggressive adenocarcinoma model of NSCLC. Additionaly, these data, which must 
be validated in larger patient cohorts, suggest a predictive value when considering both 
the genetic and expression status of MYC for monitoring outcomes and practicing 
precision medicine for patients with NSCLC and other cancers receiving immune 
checkpoint therapy. 
 
VI. Summary Discussion 
We have derived pre-clinical data supporting a role for epigenetic therapy in decreasing 
c-MYC signaling and driving a substantial anti-tumor response associated with a 
reversion of an immune evasion phenotype. We describe a novel regimen using careful 
selection of specific HDACi’s in combination with Aza. We find the inhibition of HDAC1, 
2, and 3 isoforms are key for inducing a profound proliferative arrest, imparting most of 
this efect at clinicaly relevant concentrations of ITF-2357 (Figure 11B). The inhibition of 
HDAC6 appears to play a more important role in interferon signaling (Figures 17A-D), 
possibly involving its known function for regulating Stat-1 dependent NF-kB signaling 
(Kramer et al., 2006). 
We find these HDACis can complement the therapeutic efects of Aza across a diverse 
panel of NSCLC cel lines, thus suggesting its applicability for the treatment of NSCLC 
(Figures 6 and 7). Our observation of a strong correlation between both MYC basal 
levels and degree of downregulation by Aza suggest the importance of MYC 
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assessment for the delineation of patients most likely to respond to epigenetic treatment 
(Figure 21B and 21C). 
The best indication of the translational potential for our combination epigenetic therapy 
are the phenotypic results achieved by treating two mouse models of NSCLC (Figures 
25 and 26). These models alow for our observations that the epigenetic treatment alters 
the intra-tumor localization and functional status of key immune cel populations 
(Figures 28 and 29). This occurs concurently with a decrease in MYC pathway 
signaling (Figures 27E and 27F). The importance of MYC in driving tumor formation in 
the LSL-KrasG12D mouse model has been established wherein inhibition of MYC and its 
targets has been shown to eradicate lung tumor lesions (Soucek et al., 2013). 
Although the above antitumor responses are partly driven by the direct growth inhibitory 
efects of the therapy as observed in immune incompetent mice (Figures 13A-13F), we 
also observed a significant alteration of immune populations mediated by our therapeutic 
paradigm when treating immune competent mouse models (Figures 28 and 29). The 
crucial role of the CD8+ T cels in driving the anti-tumor response is apparent from the 
significant atenuation of the anti-tumor response in the immune competent mice 
folowing CD8 depletion (Figure 31). Our observation of decreased angiogenic potential 
of tumor associated macrophages post treatment has implications in tumor 
vascularization, which is essential for the growth of large adenocarcinoma lesions 
(Figures 28A-28E). Key among these findings is the efect of epigenetic treatment 
duration on the modulation of T cel fate. A critical observation is that application of 
epigenetic treatment for limited duration induces the accumulation of activated T efector 
cels (Figure 29D), while chronic, long term treatment induces modulation away from an 
exhausted T cel phenotype, inducing a profile more indicative of the formation of 
efector-memory T cels (Figures 30B and 30C). This acquisition of a memory 
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phenotype coupled with intra-tumor accumulation of activated T-cels imparts an 
immunological landscape primed for durable response to immune checkpoint therapy 
(Ribas et al., 2016). 
A final point for high translational implications is our linking epigenetic therapy induced 
atraction of CD8+ T cels to the tumor microenvironment and the relationship of this 
event with decreased MYC signaling. An important parameter altered, which may have 
implications for the induced infiltration of CD8+ T cels into the tumor microenvironment, 
is the simultaneous upregulation of CCL5 protein secretion into the bronchioloalveolar 
compartment (Figures 32A and 32B). The forced overexpression of this secreted 
protein has been found to induce recruitment of T cels (Lavergne et al., 2004). Notably, 
others have found higher levels of CCL5 to be an independent prognostic indicator for 
longer overal survival, with an induction of an active tumor associated lymphocyte 
compartment in NSCLC patients (Moran et al., 2002). 
In patient tumors, CCL5 augmentation by epigenetic therapy may prove crucial both 
functionaly and as a biomarker in pre- and post-epigenetic treatment. As a biomarker, 
these data indicate that such findings for basal levels of CCL5 may be especialy 
valuable when combined with the other markers studied such as the genetic and 
expression status of MYC. Considering these relationships may enable the prediction of 
those patients most likely to respond to combination of epigenetic and immune therapy. 
Specificaly, based on our corolary hypothesis, patients with MYC high, CCL5 low 
tumors could be those who most benefit from this combination. 
In summary, we believe that combination epigenetic therapy induced depletion of MYC 
can remove a barrier to interferon responsiveness, potentiate T cel atraction and cause 
direct anti-proliferative actions. This coupled with the reversion of T cel exhaustion and 
acquisition of a T cel memory fate suggest the potential for use of epigenetic therapy in 
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combination with immune checkpoint blockade. Our early findings for MYC amplification 
in the one of four patients who had a much less robust initial response to immune 
checkpoint response than the others who achieved durable clinical benefit is in keeping 
with the need to further pursue these findings in the clinic (Figure 7G and H). In this 
regard, the work in our present study, and the hypotheses derived are being pursued in 
the afore mentioned clinical trial for patients with NSCLC testing our combined 
epigenetic therapy, with the DNA demethylating agent, Guadecitabine plus the HDACi, 


















Anagnostou, V., Smith, K.N., Forde, P.M., Niknafs, N., Bhatacharya, R., White, J., 
Zhang, T., Adlef, V., Phalen, J., Wali, N., et al. (2017). Evolution of Neoantigen 
Landscape during Immune Checkpoint Blockade in Non-Smal Cel Lung Cancer. 
Cancer discovery 7, 264-276. 
Bantschef, M., C. Hopf, M. M. Savitski, A. Ditmann, P. Grandi, A. M. Michon, J. Schlegl, 
Y. Abraham, I. Becher, G. Bergamini, M. Boesche, M. Deling, B. Dumpelfeld, D. 
Eberhard, C. Huthmacher, T. Mathieson, D. Poeckel, V. Reader, K. Strunk, G. 
Sweetman, U. Kruse, G. Neubauer, N. G. Ramsden and G. Drewes (2011). 
"Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC 
complexes." Nat Biotechnol 29(3): 255-265. 
Barth, T. K. and A. Imhof (2010). "Fast signals and slow marks: the dynamics of histone 
modifications." Trends Biochem Sci 35(11): 618-626. 
Baylin SB, Jones PA. (2016). Epigenetic Determinants of Cancer. Cold Spring Harb 
Perspect Biol. 1;8(9). 
Bhala, S., S. Balasubramanian, K. David, M. Sirisawad, J. Buggy, L. Mauro, S. 
Prachand, R. Miler, L. I. Gordon and A. M. Evens (2009). "PCI-24781 induces caspase 
and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and 
is synergistic with bortezomib in lymphoma cels." Clin Cancer Res 15(10): 3354-336 
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., Chow, L.Q., 
Vokes, E.E., Felip, E., Holgado, E., et al. (2015). Nivolumab versus Docetaxel in 
Advanced Nonsquamous Non-Smal-Cel Lung Cancer. The New England journal of 
medicine 373, 1627-1639. 
Boyer, L. A., M. R. Langer, K. A. Crowley, S. Tan, J. M. Denu and C. L. Peterson (2002). 
"Essential role for the SANT domain in the functioning of multiple chromatin remodeling 
enzymes." Mol Cel 10(4): 935-942. 
Bradner, J.E., West, N., Grachan, M.L., Greenberg, E.F., Haggarty, S.J., Warnow, T., 
and Mazitschek, R. (2010). Chemical phylogenetics of histone deacetylases. Nature 
chemical biology 6, 238-243. 
Cai, Y., Geutjes, E.J., de Lint, K., Roepman, P., Bruurs, L., Yu, L.R., Wang, W., van 
Blijswijk, J., Mohammad, H., de Rink, I., et al. (2014). The NuRD complex cooperates 
with DNMTs to maintain silencing of key colorectal tumor suppressor genes. Oncogene 
33, 2157-2168. 
Cai, Y., Tsai, H.C., Yen, R.C., Zhang, Y.W., Kong, X., Wang, W., Xia, L., and Baylin, 
S.B. (2017). Critical threshold levels of DNA methyltransferase 1 are required to 




Cameron, E.E., Bachman, K.E., Myohanen, S., Herman, J.G., and Baylin, S.B. (1999). 
Synergy of demethylation and histone deacetylase inhibition in the re-expression of 
genes silenced in cancer. Nature genetics 21, 103-107. 
Casey, S.C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K.N., Gouw, A.M., Baylot, V., 
Gutgemann, I., Eilers, M., et al. (2016). MYC regulates the antitumor immune response 
through CD47 and PD-L1. Science 352, 227-231. 
Charlet J, Duymich CE, Lay FD, Mundbjerg K, Dalsgaard Sørensen K, Liang G, Jones 
PA (2016). Bivalent Regions of Cytosine Methylation and H3K27 Acetylation Suggest an 
Active Role for DNA Methylation at Enhancers. Mol Cel 62(3):422-31. 
Chen, Ueda, Dodge, Wang, and Li (2003). Establishment and Maintenance of Genomic 
Methylation Paterns in Mouse Embryonic Stem Cels by Dnmt3a and Dnmt3b. Mol Cel 
23(16): 5594–5605. 
Cheng, Z., Gong, Y., Ma, Y., Lu, K., Lu, X., Pierce, L.A., Thompson, R.C., Muler, S., 
Knapp, S., and Wang, J. (2013). Inhibition of BET bromodomain targets geneticaly 
diverse glioblastoma. Clinical cancer research : an oficial journal of the American 
Association for Cancer Research 19, 1748-1759. 
Chiappineli, K.B., Strissel, P.L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., 
Rote, N.S., Cope, L.M., Snyder, A., et al. (2015). Inhibiting DNA Methylation Causes an 
Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cel 162, 
974-986. 
Codina, A., J. D. Love, Y. Li, M. A. Lazar, D. Neuhaus and J. W. Schwabe (2005). 
Structural insights into the interaction and activation of histone deacetylase 3 by nuclear 
receptor corepressors. Proc Natl Acad Sci U S A 102(17): 6009-6014. 
Cancer Genome Atlas Research Network. (2014). Comprehensive molecular profiling of 
lung adenocarcinoma. Nature ;511(7511):543-50 
Cancer Genome Atlas Research Network. (2012). Comprehensive genomic 
characterization of squamous cel lung cancers. Nature;489(7417):519-25. 
Denslow, S. A. and P. A. Wade (2007). The human Mi-2/NuRD complex and gene 
regulation. Oncogene 26(37): 5433-5438. 
Derissen, Beijnen, Schelens (2013). Concise Drug Review: Azacitidine and Decitabine. 
Oncologist. 18(5): 619–624. 
Duymich CE, Charlet J, Yang X, Jones PA, Liang G (2016). DNMT3B isoforms without 
catalytic activity stimulate gene body methylation as accessory proteins in somatic cels. 
Nat Commun. 7:11453. 
Ebert, D. H., H. W. Gabel, N. D. Robinson, N. R. Kastan, L. S. Hu, S. Cohen, A. J. 
Navarro, M. J. Lyst, R. Ekiert, A. P. Bird and M. E. Greenberg (2013). "Activity-
dependent phosphorylation of MeCP2 threonine 308 regulates interaction with NCoR." 
Nature 499(7458): 341-345. 
Falkenberg, K.J., and Johnstone, R.W. (2014). Histone deacetylases and their inhibitors 




Forneris, F., C. Binda, A. Adamo, E. Bataglioli and A. Matevi (2007). "Structural basis 
of LSD1-CoREST selectivity in histone H3 recognition." J Biol Chem 282(28): 20070-
20074. 
Fotheringham, S., M. T. Epping, L. Stimson, O. Khan, V. Wood, F. Pezzela, R. Bernards 
and N. B. La Thangue (2009). Genome-wide loss-of-function screen reveals an 
important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cel 
15(1): 57-66. 
Furlan, A., Monzani, V., Reznikov, L.L., Leoni, F., Fossati, G., Modena, D., Mascagni, P., 
and Dinarelo, C.A. (2011). Pharmacokinetics, safety and inducible cytokine responses 
during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). 
Molecular medicine 17, 353-362. 
Garon, E.B., Rizvi, N.A., Hui, R., Leighl, N., Balmanoukian, A.S., Eder, J.P., Patnaik, A., 
Aggarwal, C., Gubens, M., Horn, L., et al. (2015). Pembrolizumab for the treatment of 
non-smal-cel lung cancer. The New England journal of medicine 372, 2018-2028. 
Ghoneim, H.E., Fan, Y., Moustaki, A., Abdelsamed, H.A., Dash, P., Dogra, P., Carter, 
R., Awad, W., Neale, G., Thomas, P.G., et al. (2017). De Novo Epigenetic Programs 
Inhibit PD-1 Blockade-Mediated T Cel Rejuvenation. Cel 170, 142-157 e119. 
Gore, L., Rothenberg, M.L., O'Bryant, C.L., Schultz, M.K., Sandler, A.B., Cofin, D., 
McCoy, C., Schot, A., Scholz, C., and Eckhardt, S.G. (2008). A phase I and 
pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with 
refractory solid tumors and lymphomas. Clinical cancer research : an oficial journal of 
the American Association for Cancer Research 14, 4517-4525. 
Guenther, M. G., O. Barak and M. A. Lazar (2001). The SMRT and N-CoR corepressors 
are activating cofactors for histone deacetylase 3. Mol Cel Biol 21(18): 6091-6101. 
Gui, C. Y., L. Ngo, W. S. Xu, V. M. Richon and P. A. Marks (2004). "Histone deacetylase 
(HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated 
proteins, including HDAC1." Proc Natl Acad Sci U S A 101(5): 1241-1246. 
Herbst R.S., Heymach J.V., Lippman S.M. (2008) Lung Cancer. N Engl J Med. 
25;359(13):1367-80. 
Holz-Schietinger C, Reich NO. (2010). The inherent processivity of the human de novo 
methyltransferase 3A (DNMT3A) is enhanced by DNMT3L. J Biol Chem. 
17;285(38):29091-100. 
Hong, M., Puaux, A.L., Huang, C., Loumagne, L., Tow, C., Mackay, C., Kato, M., 
Prevost-Blondel, A., Avril, M.F., Nardin, A., et al. (2011). Chemotherapy induces 
intratumoral expression of chemokines in cutaneous melanoma, favoring T-cel 
infiltration and tumor control. Cancer research 71, 6997-7009. 
Huang da, W., Sherman, B.T., and Lempicki, R.A. (2009a). Bioinformatics enrichment 
tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic 
acids research 37, 1-13. 
112 
 
Huang da, W., Sherman, B.T., and Lempicki, R.A. (2009b). Systematic and integrative 
analysis of large gene lists using DAVID bioinformatics resources. Nature protocols 4, 
44-57. 
Huang, Y., Goel, S., Duda, D.G., Fukumura, D., and Jain, R.K. (2013). Vascular 
normalization as an emerging strategy to enhance cancer immunotherapy. Cancer 
research 73, 2943-2948. 
Huang, Y., Yuan, J., Righi, E., Kamoun, W.S., Ancukiewicz, M., Nezivar, J., 
Santosuosso, M., Martin, J.D., Martin, M.R., Vianelo, F., et al. (2012). Vascular 
normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor 
microenvironment and enhance immunotherapy. Proceedings of the National Academy 
of Sciences of the United States of America 109, 17561-17566. 
Jackson, E.L., Wilis, N., Mercer, K., Bronson, R.T., Crowley, D., Montoya, R., Jacks, T., 
and Tuveson, D.A. (2001). Analysis of lung tumor initiation and progression using 
conditional expression of oncogenic K-ras. Genes & development 15, 3243-3248. 
Jones, P.A. and Baylin, S (2014). The epigenomics of cancer. Cel; 128(4): 683–692. 
Jones, P.A., Issa, J.P., and Baylin, S. (2016). Targeting the cancer epigenome for 
therapy. Nature reviews Genetics 17, 630-641. 
Jones, S. F., J. R. Infante, D. R. Spigel, N. W. Peacock, D. S. Thompson, F. A. Greco, 
W. McCuloch and H. A. Burris, 3rd (2012). "Phase 1 results from a study of romidepsin 
in combination with gemcitabine in patients with advanced solid tumors." Cancer Invest 
30(6): 481-486. 
Juergens, R.A., Wrangle, J., Vendeti, F.P., Murphy, S.C., Zhao, M., Coleman, B., 
Sebree, R., Rodgers, K., Hooker, C.M., Franco, N., et al. (2011). Combination epigenetic 
therapy has eficacy in patients with refractory advanced non-smal cel lung cancer. 
Cancer discovery 1, 598-607. 
Khan, O., S. Fotheringham, V. Wood, L. Stimson, C. Zhang, F. Pezzela, M. Duvic, D. J. 
Kerr and N. B. La Thangue (2010). "HR23B is a biomarker for tumor sensitivity to HDAC 
inhibitor-based therapy." Proc Natl Acad Sci U S A 107(14): 6532-6537 
Kelar, A., Egan, C., and Morris, D. (2015). Preclinical Murine Models for Lung Cancer: 
Clinical Trial Applications. BioMed research international 2015, 621324. 
Kim, M., L. A. Thompson, S. D. Wenger and C. L. O'Bryant (2012). "Romidepsin: a 
histone deacetylase inhibitor for refractory cutaneous T-cel lymphoma." Ann 
Pharmacother 46(10): 1340-1348. 
Kramer, O.H., Baus, D., Knauer, S.K., Stein, S., Jager, E., Stauber, R.H., Grez, M., 
Pfitzner, E., and Heinzel, T. (2006). Acetylation of Stat1 modulates NF-kappaB activity. 
Genes & development 20, 473-485. 
Lavergne, E., Combadiere, C., Iga, M., Boissonnas, A., Bonduele, O., Maho, M., Debre, 
P., and Combadiere, B. (2004). Intratumoral CC chemokine ligand 5 overexpression 




Lee, H. Z., V. E. Kwitkowski, P. L. Del Vale, M. S. Ricci, H. Saber, B. A. Habtemariam, 
J. Bulock, E. Bloomquist, Y. Li Shen, X. H. Chen, J. Brown, N. Mehrotra, S. Dorf, R. 
Charlab, R. C. Kane, E. Kaminskas, R. Justice, A. T. Farel and R. Pazdur (2015). "FDA 
Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory 
Peripheral T-cel Lymphoma." Clin Cancer Res 21(12): 2666-2670. 
Li, H., Chiappineli, K.B., Guzzeta, A.A., Easwaran, H., Yen, R.W., Vatapali, R., Topper, 
M.J., Luo, J., Connoly, R.M., Azad, N.S., et al. (2014). Immune regulation by low doses 
of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial 
cancers. Oncotarget 5, 587-598. 
Lombardi, P. M., K. E. Cole, D. P. Dowling and D. W. Christianson (2011). "Structure, 
mechanism, and inhibition of histone deacetylases and related metaloenzymes." Cur 
Opin Struct Biol 21(6): 735-743. 
Mann, B. S., J. R. Johnson, K. He, R. Sridhara, S. Abraham, B. P. Booth, L. Verbois, D. 
E. Morse, J. M. Jee, S. Pope, R. S. Harapanhali, R. Dagher, A. Farrel, R. Justice and 
R. Pazdur (2007). "Vorinostat for treatment of cutaneous manifestations of advanced 
primary cutaneous T-cel lymphoma." Clin Cancer Res 13(8): 2318-2322. 
Mann, B. S., J. R. Johnson, M. H. Cohen, R. Justice and R. Pazdur (2007). "FDA 
approval summary: vorinostat for treatment of advanced primary cutaneous T-cel 
lymphoma." Oncologist 12(10): 1247-1252. 
Meilinger, Felinger, Bultmann, Rothbauer, Bonapace, Klinkert, Spada, Leonhardt. 
(2009) Np95 interacts with de novo DNA methyltransferases, Dnmt3a and Dnmt3b, and 
mediates epigenetic silencing of the viral CMV promoter in embryonic stem cels. EMBO 
Rep. 10(11): 1259–1264. 
Moran, C.J., Arenberg, D.A., Huang, C.C., Giordano, T.J., Thomas, D.G., Misek, D.E., 
Chen, G., Iannetoni, M.D., Orringer, M.B., Hanash, S., et al. (2002). RANTES 
expression is a predictor of survival in stage I lung adenocarcinoma. Clinical cancer 
research : an oficial journal of the American Association for Cancer Research 8, 3803-
3812. 
Moreno-Bost, A., Szmania, S., Stone, K., Garg, T., Hoering, A., Szymonifka, J., 
Shaughnessy, J., Jr., Barlogie, B., Prentice, H.G., and van Rhee, F. (2011). Epigenetic 
modulation of MAGE-A3 antigen expression in multiple myeloma folowing treatment 
with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor 
MGCD0103. Cytotherapy 13, 618-628. 
New, M., H. Olzscha and N. B. La Thangue (2012). "HDAC inhibitor-based therapies: 
can we interpret the code?" Mol Oncol 6(6): 637-656. 
Phiel, C. J., F. Zhang, E. Y. Huang, M. G. Guenther, M. A. Lazar and P. S. Klein (2001). 
"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood 
stabilizer, and teratogen." J Biol Chem 276(39): 36734-36741. 
Oi, S., Natsume, A., Ito, M., Kondo, Y., Shimato, S., Maeda, Y., Saito, K., and 
Wakabayashi, T. (2009). Synergistic induction of NY-ESO-1 antigen expression by a 
novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma 
cels. Journal of neuro-oncology 92, 15-22. 
114 
 
Okayama, H., Saito, M., Oue, N., Weiss, J.M., Staufer, J., Takenoshita, S., Wiltrout, 
R.H., Hussain, S.P., and Haris, C.C. (2013). NOS2 enhances KRAS-induced lung 
carcinogenesis, inflammation and microRNA-21 expression. International journal of 
cancer 132, 9-18. 
Perissi, V., K. Jepsen, C. K. Glass and M. G. Rosenfeld (2010). "Deconstructing 
repression: evolving models of co-repressor action." Nat Rev Genet 11(2): 109-123. 
Prince, H. M., M. J. Bishton and S. J. Harison (2009). "Clinical studies of histone 
deacetylase inhibitors." Clin Cancer Res 15(12): 3958-3969 
Rao, R., S. Naluri, R. Kolhe, Y. Yang, W. Fiskus, J. Chen, K. Ha, K. M. Buckley, R. 
Balusu, V. Coothankandaswamy, A. Joshi, P. Atadja and K. N. Bhala (2010). 
"Treatment with panobinostat induces glucose-regulated protein 78 acetylation and 
endoplasmic reticulum stress in breast cancer cels." Mol Cancer Ther 9(4): 942-952. 
Rasheed, W.K., Johnstone, R.W., and Prince, H.M. (2007). Histone deacetylase 
inhibitors in cancer therapy. Expert opinion on investigational drugs 16, 659-678. 
Reck, M., Rodriguez-Abreu, D., Robinson, A.G., Hui, R., Csoszi, T., Fulop, A., Gotfried, 
M., Peled, N., Tafreshi, A., Cufe, S., et al. (2016). Pembrolizumab versus 
Chemotherapy for PD-L1-Positive Non-Smal-Cel Lung Cancer. The New England 
journal of medicine 375, 1823-1833. 
Richardson, P. G., R. D. Harvey, J. P. Laubach, P. Moreau, S. Lonial and J. F. San-
Miguel (2016). "Panobinostat for the treatment of relapsed or relapsed/refractory multiple 
myeloma: pharmacology and clinical outcomes." Expert Rev Clin Pharmacol 9(1): 35-48. 
Ribas, A., Shin, D.S., Zaretsky, J., Frederiksen, J., Cornish, A., Avramis, E., Seja, E., 
Kivork, C., Siebert, J., Kaplan-Lefko, P., et al. (2016). PD-1 Blockade Expands 
Intratumoral Memory T Cels. Cancer immunology research 4, 194-203. 
Rinaldi L, Data D, Serrat J, Morey L, Solanas G, Avgustinova A, Blanco E, Pons JI, 
Matalanas D, Von Kriegsheim A, Di Croce L, Benitah SA. (2016) Cel Stem Cel 
19(4):491-501. 
Rizvi, N.A., Helmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., 
Yuan, J., Wong, P., Ho, T.S., et al. (2015). Cancer immunology. Mutational landscape 
determines sensitivity to PD-1 blockade in non-smal cel lung cancer. Science 348, 124-
128. 
Ropero, S. and M. Esteler (2007). "The role of histone deacetylases (HDACs) in human 
cancer." Mol Oncol 1(1): 19-25. 
Rose, N. R. and R. J. Klose (2014). "Understanding the relationship between DNA 
methylation and histone lysine methylation." Biochim Biophys Acta 1839(12): 1362-1372. 
Roulois, D., Loo Yau, H., Singhania, R., Wang, Y., Danesh, A., Shen, S.Y., Han, H., 
Liang, G., Jones, P.A., Pugh, T.J., et al. (2015). DNA-Demethylating Agents Target 




Ryan, Q.C., Headlee, D., Acharya, M., Sparreboom, A., Trepel, J.B., Ye, J., Figg, W.D., 
Hwang, K., Chung, E.J., Murgo, A., et al. (2005). Phase I and pharmacokinetic study of 
MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid 
tumors or lymphoma. Journal of clinical oncology : oficial journal of the American 
Society of Clinical Oncology 23, 3912-3922. 
San-Miguel, J. F., P. G. Richardson, A. Gunther, O. Sezer, D. Siegel, J. Blade, R. 
LeBlanc, H. Sutherland, M. Sopala, K. K. Mishra, S. Mu, P. M. Bourquelot, M. Victoria 
Mateos and K. C. Anderson (2013). "Phase Ib study of panobinostat and bortezomib in 
relapsed or relapsed and refractory multiple myeloma." J Clin Oncol 31(29): 3696-3703. 
Schlee, M., Holzel, M., Bernard, S., Mailhammer, R., Schuhmacher, M., Reschke, J., 
Eick, D., Marinkovic, D., Wirth, T., Rosenwald, A., et al. (2007a). C-myc activation 
impairs the NF-kappaB and the interferon response: implications for the pathogenesis of 
Burkit's lymphoma. International journal of cancer 120, 1387-1395. 
Schlee, M., Schuhmacher, M., Holzel, M., Laux, G., and Bornkamm, G.W. (2007b). c-
MYC impairs immunogenicity of human B cels. Advances in cancer research 97, 167-
188. 
Shao, Y., Z. Gao, P. A. Marks and X. Jiang (2004). "Apoptotic and autophagic cel death 
induced by histone deacetylase inhibitors." Proc Natl Acad Sci U S A 101(52): 18030-
18035. 
Soucek, L., Whitfield, J.R., Sodir, N.M., Masso-Vales, D., Serano, E., Karnezis, A.N., 
Swigart, L.B., and Evan, G.I. (2013). Inhibition of Myc family proteins eradicates KRas-
driven lung cancer in mice. Genes & development 27, 504-513. 
Stengel, S., Fiebig, U., Kurth, R., and Denner, J. (2010). Regulation of human 
endogenous retrovirus-K expression in melanomas by CpG methylation. Genes, 
chromosomes & cancer 49, 401-411. 
Stresemann C, Lyko F. (2008). Modes of action of the DNA methyltransferase inhibitors 
azacytidine and decitabine. Int J Cancer. 123(1):8-13. 
Stimson, L. and N. B. La Thangue (2009). "Biomarkers for predicting clinical responses 
to HDAC inhibitors." Cancer Let 280(2): 177-183 
Strissel, P.L., Ruebner, M., Thiel, F., Wachter, D., Ekici, A.B., Wolf, F., Thieme, F., 
Ruprecht, K., Beckmann, M.W., and Strick, R. (2012). Reactivation of codogenic 
endogenous retroviral (ERV) envelope genes in human endometrial carcinoma and 
prestages: Emergence of new molecular targets. Oncotarget 3, 1204-1219. 
Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gilete, M.A., 
Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., et al. (2005). Gene set 
enrichment analysis: a knowledge-based approach for interpreting genome-wide 
expression profiles. Proceedings of the National Academy of Sciences of the United 
States of America 102, 15545-15550. 
Talevich, E., Shain, A.H., Boton, T., and Bastian, B.C. (2016). CNVkit: Genome-Wide 
Copy Number Detection and Visualization from Targeted DNA Sequencing. PLoS 
computational biology 12, e1004873. 
116 
 
Tsai, H.C., Li, H., Van Neste, L., Cai, Y., Robert, C., Rassool, F.V., Shin, J.J., Harbom, 
K.M., Beaty, R., Pappou, E., et al. (2012). Transient low doses of DNA-demethylating 
agents exert durable antitumor efects on hematological and epithelial tumor cels. 
Cancer cel 21, 430-446. 
Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J., Robert, L., 
Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014). PD-1 blockade 
induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571. 
Verdin, E., F. Dequiedt and H. G. Kasler (2003). "Class I histone deacetylases: versatile 
regulators." Trends Genet 19(5): 286-293. 
Wang, Y., H. Zhang, Y. Chen, Y. Sun, F. Yang, W. Yu, J. Liang, L. Sun, X. Yang, L. Shi, 
R. Li, Y. Li, Y. Zhang, Q. Li, X. Yi and Y. Shang (2009). "LSD1 is a subunit of the NuRD 
complex and targets the metastasis programs in breast cancer." Cel 138(4): 660-672. 
Weiser, T.S., Guo, Z.S., Ohnmacht, G.A., Parkhurst, M.L., Tong-On, P., Marincola, F.M., 
Fischete, M.R., Yu, X., Chen, G.A., Hong, J.A., et al. (2001). Sequential 5-Aza-2 
deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentialy in 
cancer cels and facilitates their recognition by cytolytic T lymphocytes specific for NY-
ESO-1. Journal of immunotherapy 24, 151-161. 
Wherry, E.J., Ha, S.J., Kaech, S.M., Haining, W.N., Sarkar, S., Kalia, V., Subramaniam, 
S., Blatman, J.N., Barber, D.L., and Ahmed, R. (2007). Molecular signature of CD8+ T 
cel exhaustion during chronic viral infection. Immunity 27, 670-684. 
Wherry, E.J., and Kurachi, M. (2015). Molecular and celular insights into T cel 
exhaustion. Nature reviews Immunology 15, 486-499. 
Wit, O. and R. Lindemann (2009). "HDAC inhibitors: magic bulets, dirty drugs or just 
another targeted therapy." Cancer Let 280(2): 123-124. 
Wit, O., H. E. Deubzer, T. Milde and I. Oehme (2009). "HDAC family: What are the 
cancer relevant targets?" Cancer Let 277(1): 8-21. 
Wrangle, J., Wang, W., Koch, A., Easwaran, H., Mohammad, H.P., Vendeti, F., 
Vancriekinge, W., Demeyer, T., Du, Z., Parsana, P., et al. (2013). Alterations of immune 
response of Non-Smal Cel Lung Cancer with Azacytidine. Oncotarget 4, 2067-2079. 
Xia L, Huang W, Belani M, Seidman MM, Wu K, Fan D, Nie Y, Cai Y, Zhang YW, Yu 
LR, Li H, Zahnow CA, Xie W, Chiu Yen RW, Rassool FV, Baylin SB. (2017). CHD4 Has 
Oncogenic Functions in Initiating and Maintaining Epigenetic Suppression of Multiple 
Tumor Suppressor Genes. Cancer Cel;31(5):653-668. 
Yang, W. M., S. C. Tsai, Y. D. Wen, G. Fejer and E. Seto (2002). Functional domains of 
histone deacetylase-3. J Biol Chem 277(11): 9447-9454. 
Yang, M., C. B. Gocke, X. Luo, D. Borek, D. R. Tomchick, M. Machius, Z. Otwinowski 
and H. Yu (2006). "Structural basis for CoREST-dependent demethylation of 
nucleosomes by the human LSD1 histone demethylase." Mol Cel 23(3): 377-387. 
Yardley, D. A., R. R. Ismail-Khan, B. Melichar, M. Lichinitser, P. N. Munster, P. M. Klein, 
S. Cruickshank, K. D. Miler, M. J. Lee and J. B. Trepel (2013). "Randomized phase I, 
117 
 
double-blind, placebo-controled study of exemestane with or without entinostat in 
postmenopausal women with localy recurrent or metastatic estrogen receptor-positive 
breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor." J Clin 
Oncol 31(17): 2128-2135. 
Zahnow, C.A., Topper, M., Stone, M., Murray-Stewart, T., Li, H., Baylin, S.B., and 
Casero, R.A., Jr. (2016). Inhibitors of DNA Methylation, Histone Deacetylation, and 
Histone Demethylation: A Perfect Combination for Cancer Therapy. Advances in cancer 
research 130, 55-111. 
Zehn, D., and Whery, E.J. (2015). Immune Memory and Exhaustion: Clinicaly Relevant 
Lessons from the LCMV Model. Advances in experimental medicine and biology 850, 
137-152. 
Zhang, J., M. Kalkum, B. T. Chait and R. G. Roeder (2002). "The N-CoR-HDAC3 nuclear 
receptor corepressor complex inhibits the JNK pathway through the integral subunit 

















IX. Biographical Sketch 
Michael J. Topper 
 





2012-Present Ph.D. Celular and Molecular Medicine, Johns Hopkins 
University, School of Medicine, Baltimore, Maryland 
 
2011 B.S. Biological Sciences, University of Maryland, Baltimore 






2012-Present  Doctoral Student, Celular and Molecular Medicine Program, 
Johns Hopkins University School of Medicine, Baltimore, MD 
    Principal Investigator: Stephen Baylin, M.D. 
Dissertation Title: Epigenetic therapy ties MYC depletion to 
reversing immune evasion and treating lung cancer 
 
2008-2010  Undergraduate Research Assistant, University of Maryland, 
Baltimore County. Baltimore, MD 
    Principal Investigator: Jef Leips, Ph.D. 





Selected Poster Presentations 
 
Sequential Azacitidine and histone deacetylase inhibition induces a potent anti-tumor 
response in a geneticaly engineered mouse model of non-smal cel lung cancer. AACR 
Annual Meeting 2017, Washington D.C. 
 
Combination Azacitidine and histone deacetylase inhibition induces a multi factorial 
synergistic anti-tumor response in non-smal cel lung cancer. Sidney Kimmel 
Comprehensive Cancer Center Research Felows Day 2016, (Poster First Place 
Clinical/Translational category). Baltimore, MD 
 
Combination Azacitidine and histone deacetylase inhibition induces a multi factorial 
synergistic anti-tumor response in non-smal cel lung cancer (NSCLC) AACR Annual 




Genome wide association tests for age-specific immunocompetence in Drosophila. 





Topper MJ, Vaz M, Chiappineli K, Shields CD, Niknafs N, Chiu Yen RC, Wenzel A, 
Hicks J, Balew M, Stone M, Tran P, Zahnow CA, Helmann M, Anagnostou V, Strissel P, 
Strick R, Velculescu V, Baylin SB (2017) Epigenetic therapy ties MYC depletion to 
reversing immune evasion and treating lung cancer. Cel, accepted manuscript. 
 
Zahnow CA, Topper M, Stone M, Murray-Stewart T, Li H, Baylin SB, Casero RA Jr. 
(2016). Inhibitors of DNA Methylation, Histone Deacetylation, and Histone 
Demethylation: A Perfect Combination for Cancer Therapy. Adv Cancer Res., 130:55-
111 
Vendeti FP, Topper M, Huang P, Dobromilskaya I, Easwaran H, Wrangle J, Baylin SB, 
Poirier JT, Rudin CM. (2015). Evaluation of azacitidine and entinostat as sensitization 
agents to cytotoxic chemotherapy in preclinical models of non-smal cel lung cancer. 
Oncotarget;6(1):56-70. 
Li H, Chiappineli KB, Guzzeta AA, Easwaran H, Yen RW, Vatapali R, Topper MJ, Luo 
J, Connoly RM, Azad NS, Stearns V, Pardol DM, Davidson N, Jones PA, Slamon DJ, 
Baylin SB, Zahnow CA, Ahuja N. (2014). Immune regulation by low doses of the DNA 
methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. 
Oncotarget;5(3):587-98. 
 
 
 
 
 
 
 
 
 
